<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TPX</journal-id>
<journal-id journal-id-type="hwp">sptpx</journal-id>
<journal-id journal-id-type="nlm-ta">Toxicol Pathol</journal-id>
<journal-title>Toxicologic Pathology</journal-title>
<issn pub-type="ppub">0192-6233</issn>
<issn pub-type="epub">1533-1601</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0192623311436185</article-id>
<article-id pub-id-type="publisher-id">10.1177_0192623311436185</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Regular Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Immunohistochemical Features of 3,3′,4,4′-Tetrachloroazobenzene-Induced Rat Gingival Lesions </article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ramot</surname>
<given-names>Yuval</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623311436185">1*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vered</surname>
<given-names>Marilena</given-names>
</name>
<xref ref-type="aff" rid="aff2-0192623311436185">2*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Malarkey</surname>
<given-names>David E.</given-names>
</name>
<xref ref-type="aff" rid="aff3-0192623311436185">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hooth</surname>
<given-names>Michelle J.</given-names>
</name>
<xref ref-type="aff" rid="aff3-0192623311436185">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Painter</surname>
<given-names>J. Todd</given-names>
</name>
<xref ref-type="aff" rid="aff4-0192623311436185">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dayan</surname>
<given-names>Dan</given-names>
</name>
<xref ref-type="aff" rid="aff2-0192623311436185">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Clayton</surname>
<given-names>Natasha</given-names>
</name>
<xref ref-type="aff" rid="aff5-0192623311436185">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Masinde</surname>
<given-names>Tiwanda</given-names>
</name>
<xref ref-type="aff" rid="aff5-0192623311436185">5</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Nyska</surname>
<given-names>Abraham</given-names>
</name>
<xref ref-type="aff" rid="aff6-0192623311436185">6</xref>
<xref ref-type="corresp" rid="corresp1-0192623311436185"/>
</contrib>
</contrib-group>
<aff id="aff1-0192623311436185">
<label>1</label>Hadassah–Hebrew University Medical Center, Jerusalem, Israel</aff>
<aff id="aff2-0192623311436185">
<label>2</label>Department of Oral Pathology and Oral Medicine, School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel</aff>
<aff id="aff3-0192623311436185">
<label>3</label>National Toxicology Program, National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, North Carolina, USA</aff>
<aff id="aff4-0192623311436185">
<label>4</label>Integrated Laboratory Systems, Inc. Research Triangle Park, North Carolina, USA</aff>
<aff id="aff5-0192623311436185">
<label>5</label>Laboratory of Immunohistochemistry, Cellular and Molecular Pathology Branch, National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, North Carolina, USA</aff>
<aff id="aff6-0192623311436185">
<label>6</label>Toxicologic pathologist, Tel Aviv University, Tel Aviv and Timrat, Israel</aff>
<author-notes>
<corresp id="corresp1-0192623311436185">Abraham Nyska, Toxicological Pathologist, Haharuv 18, P.O. Box 184, Timrat, Israel 36576, Israel; e-mail: <email>anyska@bezeqint.net</email>
</corresp>
<fn fn-type="other" id="fn1-0192623311436185">
<p>*Yuval Ramot and Marilena Vered contributed equally to this work.</p></fn>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2012</year>
</pub-date>
<volume>40</volume>
<issue>4</issue>
<fpage>577</fpage>
<lpage>592</lpage>
<permissions>
<copyright-statement>© 2012 by The Author(s)</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Society of Toxicologic Pathology</copyright-holder>
</permissions>
<abstract>
<p>Gingival lesions of squamous hyperplasia, cystic keratinizing hyperplasia (CKH), and squamous cell carcinoma (SCC) can be induced in rats treated by chronic gavage with 10–100 mg/kg 3,3′,4,4′-tetrachloroazobenzene. We evaluated gingival squamous hyperplasia (GSH), CKH, and SCC for the immunohistochemical pattern of expression of carcinogenesis-associated markers. The 3 types of lesions and controls were stained with proliferation markers (proliferating cell nuclear antigen [PCNA] and cyclin-D1), tumor-suppressor markers (β-catenin and mammary serine protease inhibitor [maspin]) and stroma-related markers (α-smooth muscle actin [SMA] and osteonectin/SPARC). The lesions had common immunohistochemical characteristics that differed in their expression patterns among the various diagnoses. PCNA and cyclin-D1 expression was higher in GSH, CKH, and SCC than in controls. The normal membranous expression of β-catenin was lower in GSH, and almost absent in CKH and SCC. Maspin expression was similar in GSH and controls, whereas both CKH and SCC showed decreased expression. SMA and/or osteonectin/SPARC were seen in stromal cells in CKH and SCC. Collectively, there appears to be a progression from hyperplastic and cystic lesions toward malignancy based on the morphological changes, supported by the expression of carcinogenesis-associated proteins. The exact sequence of events leading to SCC remains to be defined in a time-dependent manner.</p>
</abstract>
<kwd-group>
<kwd>gingival squamous hyperplasia</kwd>
<kwd>squamous cell carcinoma</kwd>
<kwd>rat</kwd>
<kwd>TCAB</kwd>
<kwd>cystic keratinizing hyperplasia.</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0192623311436185">
<title>Introduction</title>
<p>The U.S. National Toxicology Program (NTP) has recently performed a series of two-year bioassays in Harlan Sprague-Dawley rats in order to evaluate the pathology and carcinogenicity induced by chronic gavage exposure to dioxin and dioxin-like compounds (DLCs). These assays revealed an array of neoplastic and non-neoplastic effects, including, for example, cholangiocarcinoma and/or hepatocellular adenoma of the liver and cystic keratinizing epithelioma of the lungs (<xref ref-type="bibr" rid="bibr8-0192623311436185">Brix et al. 2004</xref>; <xref ref-type="bibr" rid="bibr44-0192623311436185">Nyska et al. 2004</xref>; <xref ref-type="bibr" rid="bibr58-0192623311436185">Tani et al. 2004</xref>; <xref ref-type="bibr" rid="bibr68-0192623311436185">Walker et al. 2006</xref>; <xref ref-type="bibr" rid="bibr80-0192623311436185">Yoshizawa et al. 2005</xref>). In addition, oral lesions, including gingival squamous hyperplasia (GSH) and/or squamous cell carcinoma (SCC) were increased in treated rats in all studies except polychlorinated biphenyl (PCB) 153 (<xref ref-type="bibr" rid="bibr80-0192623311436185">Yoshizawa et al. 2005</xref>). Oral tumors in rats have also been reported with other chemicals examined by the NTP, thus highlighting the oral mucosa as a prominent target organ in toxicity studies (e.g., benzene, chloroprene, and others; <xref ref-type="bibr" rid="bibr80-0192623311436185">Yoshizawa et al. 2005</xref>).</p>
<p>The NTP also conducted a two-year chronic gavage study in rats using 3,3′,4,4′-tetrachloroazobenzene (TCAB), a DLC formed as a byproduct during the manufacture of 3,4-dichloroaniline or its herbicidal derivatives, and following 3,4-dichloroaniline photolysis and biolysis (<xref ref-type="bibr" rid="bibr30-0192623311436185">Hill et al. 1981</xref>; <xref ref-type="bibr" rid="bibr48-0192623311436185">Poland et al. 1976</xref>; <xref ref-type="bibr" rid="bibr51-0192623311436185">Ramot et al. 2009</xref>; <xref ref-type="bibr" rid="bibr56-0192623311436185">Singh et al. 2010</xref>). Humans can be exposed to TCAB either as occupational exposure during the manufacture of 3,4-dichloroaniline or application of herbicides containing TCAB, or as non-occupational exposure during consumption of food contaminated with TCAB (Ramot et al. 2009; <xref ref-type="bibr" rid="bibr56-0192623311436185">Singh et al. 2010</xref>).</p>
<p>The molecular factors involved in oral carcinogenesis are extensively evaluated and reviewed by <xref ref-type="bibr" rid="bibr11-0192623311436185">Choi and Myers (2008)</xref>. In the present study, we intended to employ a panel of markers known to operate within the epithelial and subjacent stromal cells. The former included proliferating cell nuclear antigen (PCNA), which is important for both DNA synthesis and DNA repair (<xref ref-type="bibr" rid="bibr33-0192623311436185">Kato et al. 2011</xref>; <xref ref-type="bibr" rid="bibr39-0192623311436185">Maga and Hubscher 2003</xref>); cyclin D1, which controls the cellular mitotic activity (<xref ref-type="bibr" rid="bibr18-0192623311436185">Diehl 2002</xref>; <xref ref-type="bibr" rid="bibr23-0192623311436185">Hall and Peters 1996</xref>); β-catenin, which in normal conditions is located at the cell membrane and acts as a key factor in the intercellular adherence mechanism, whereas in pathological circumstances it is found in a nuclear location and acts as a transcription factor for a number of pro-tumorogenic genes (<xref ref-type="bibr" rid="bibr12-0192623311436185">Daa et al. 2004</xref>; <xref ref-type="bibr" rid="bibr45-0192623311436185">Oyama et al. 1994</xref>; <xref ref-type="bibr" rid="bibr49-0192623311436185">Pollack et al. 1997</xref>; <xref ref-type="bibr" rid="bibr54-0192623311436185">Shiozaki et al. 1996</xref>; <xref ref-type="bibr" rid="bibr81-0192623311436185">Zhurinsky et al. 2000</xref>); and mammary serine inhibitory protein (maspin), which is considered as a tumor suppressor factor (<xref ref-type="bibr" rid="bibr4-0192623311436185">Bello et al. 2011</xref>). The stroma-related markers included α-smooth muscle actin (α-SMA), which is expressed in cells with a myofibroblastic phenotype (cancer-associated fibroblasts) that are involved in tumor proliferation and invasion (<xref ref-type="bibr" rid="bibr64-0192623311436185">Vered et al. 2007</xref>; <xref ref-type="bibr" rid="bibr65-0192623311436185">Vered et al. 2010</xref>); and osteonectin/cystine-rich acidic secreted protein (SPARC), which is beneficial to tumor cells in terms of angiogenesis, proliferation, and migration (<xref ref-type="bibr" rid="bibr10-0192623311436185">Chlenski and Cohn 2010</xref>; <xref ref-type="bibr" rid="bibr47-0192623311436185">Podhajcer et al. 2008</xref>).</p>
<p>Therefore, we aimed to use this TCAB model to immunohistochemically characterize, for the first time, the different types of lesions diagnosed in the gingiva of the experimental rats.</p>
</sec>
<sec id="section2-0192623311436185" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section3-0192623311436185">
<title>Chemical</title>
<p>3,3′,4,4′-Tetrachloroazobenzene (CAS No. 14047-09-7) was obtained from AccuStandard, Inc. (New Haven, CT) in one lot. 3,3′,4,4′-Tetrachloroazobenzene was identified by infrared and proton nuclear magnetic resonance spectroscopy, by gas chromatography (GC) coupled with mass spectrometry, and by melting point analysis. The purity of the TCAB was determined by Karl Fischer titration to determine moisture content; elemental analysis for carbon, hydrogen, nitrogen, and chlorine; and GC with flame ionization detection, which indicated purity of 99.8% or greater. Purity of TCAB was analyzed several times during the study; no change was observed over the duration of the study. Dose formulations were prepared for administration by gavage by mixing TCAB in a corn oil vehicle containing 1% USP-grade acetone; they were prepared fresh approximately once a month and were shown to be stable during that period of time. Pre- and post-administration analyses were performed using a GC assay with electron capture detection. All analyzed dose formulations were within 10% of the target concentrations.</p>
</sec>
<sec id="section4-0192623311436185">
<title>Animals and Housing</title>
<p>The studies were conducted in the AAALAC-accredited facility of Battelle Columbus Laboratories (Columbus, OH). Animal use was in accordance with the United States Public Health Service policy on humane care and use of laboratory animals and the Guide for the Care and Use of Laboratory Animals (<xref ref-type="bibr" rid="bibr83-0192623311436185">National Research Council 1996</xref>). In addition, these studies were conducted in compliance with the United States Food and Drug Administration (FDA) Good Laboratory Practice Regulations (<xref ref-type="bibr" rid="bibr82-0192623311436185">FDA 1987</xref>). Animals were male and female Harlan Sprague-Dawley rats (Harlan Sprague-Dawley, Inc., Indianapolis, IN); they underwent health screening during a quarantine period of thirteen (males) or fourteen (females) days and were released for study when about five weeks old. They were randomly assigned to their respective experimental groups and permanently identified by tail tattoo. Male rats were housed three per cage, and female rats were housed five per cage; all were kept in solid-bottom polycarbonate cages (Lab Products, Inc., Seaford, DE) suspended on stainless steel racks. Filtered room air was supplied at the rate of at least ten room-changes per hour. The rats were maintained at 72°F ± 3°F, with a relative humidity of 50% ± 15% and a light/dark cycle of twelve hours each. Tap water and feed (irradiated NTP-2000 pelleted diet, Zeigler Bros., Inc., Gardeners, PA) were available ad libitum.</p>
</sec>
<sec id="section5-0192623311436185">
<title>Experimental Design</title>
<p>Groups of fifty male and fifty female rats were administered 10, 30, or 100 mg TCAB/kg by gavage in corn oil and acetone (99:1), five days per week for two years. The total dosing volume was 2.5 mL/kg body weight. The dose levels were selected based on the results from NTP three-month toxicity studies (<xref ref-type="bibr" rid="bibr43-0192623311436185">NTP 2009</xref>; <xref ref-type="bibr" rid="bibr62-0192623311436185">van Birgelen et al. 1999</xref>). All rats were observed twice daily for morbidity and once a month for clinical findings. Moribund animals were sacrificed and necropsied. Health monitoring via sentinel animals showed no evidence of any significant rodent pathogens.</p>
</sec>
<sec id="section6-0192623311436185">
<title>Pathology</title>
<p>Animals were euthanized by carbon dioxide asphyxiation. Complete necropsies were performed on all animals, whether they died early or were sacrificed at termination<bold>
</bold>, using standardized methodology. At necropsy, tissues, including masses and macroscopic abnormalities, were removed and fixed in 10% neutral buffered formalin. The maxillae, including the nose, were decalcified in a 5% nitric acid decal solution (Poly Scientific, Inc., Bay Shore, NY) for three days. Three nasal sections that included oral tissues were examined. The maxilla was trimmed just posterior to the upper incisors (Section I), midway between the incisors and first molar at the anterior surface of the incisive papilla (Section II), and at the middle of the first molar (Section III). After fixation and/or decalcification in a 5% nitric acid decal solution (Poly Scientific, Inc., Bay Shore, NY) for three days, all of the tissues were trimmed, dehydrated, cleared, embedded in paraffin, sectioned into 5-µm–thick sections, stained with hematoxylin and eosin (H&amp;E), and examined microscopically. The severity of lesions, based on their relative extent, was graded on a four-point scale of 1 = minimal, 2 = mild, 3 = moderate, and 4 = marked. The pathology results underwent comprehensive NTP peer review by Pathology Working Group pathologists (<xref ref-type="bibr" rid="bibr7-0192623311436185">Boorman et al. 2002</xref>). The tongue and mandible were not routinely examined histopathologically, and no gross abnormality was observed in these organs. Additional details regarding the pathology data generation, quality assurance review, and the NTP Pathology Working Group are available elsewhere (<xref ref-type="bibr" rid="bibr43-0192623311436185">NTP 2009</xref>).</p>
</sec>
<sec id="section7-0192623311436185">
<title>Immunohistochemical Analysis</title>
<p>As the incidence of the treatment-related gingival lesions was relatively comparable between the sexes, we used samples from five control male rats and from twelve high-dose male rats: five different rats that showed GSH, five different rats that showed CKH, and five rats that showed SCC (two different rats, and three that had also either GSH or CKH). All sections were stained for previously characterized immunohistochemical markers for squamous cell proliferation and carcinogenesis (<xref ref-type="table" rid="table1-0192623311436185">Table 1</xref>, http://www.niehs.nih.gov/research/atniehs/labs/lep/path-support/immuno/protocols.cfm). These particular markers were the following: SPARC (Santa Cruz Biotechnology, Santa Cruz, CA), maspin (Santa Cruz Biotechnology), α-SMA (Abcam, Inc., Cambridge, MA), β-catenin (Santa Cruz Biotechnology), cyclin D1 (Cell Marque, Rocklin, CA), and PCNA (Santa Cruz Biotechnology). All the markers were stained manually using the the avidin-biotin complex (ABC) technique except β-catenin, which was performed on the Discovery XT Automated System (Ventana Medical Systems, Tucson, AZ) using the OmniMap anti-Rabbit Polymer Detection Kit. The system’s CC1 solution was used for antigen retrieval, and the primary antibody was incubated at 1:500 for sixty minutes without heat. For the manual stains, formalin-fixed, paraffin-embedded tissue sections were deparaffinized in xylene and rehydrated through graded ethanol. Endogenous peroxidase blocking was then performed by immersing the sections in 3% H<sub>2</sub>O<sub>2</sub> for fifteen minutes.</p>
<table-wrap id="table1-0192623311436185" position="float">
<label>Table 1.</label>
<caption>
<p>Staining Protocols for the Immunohistochemical Markers Used in the Current Study</p>
</caption>
<graphic alternate-form-of="table1-0192623311436185" xlink:href="10.1177_0192623311436185-table1.tif"/>
<table>
<thead>
<tr>
<th>Antibody</th>
<th>Epitope retrieval</th>
<th>Block</th>
<th>Primary antibody (dilution)</th>
<th>Negative control</th>
<th>Secondary antibody</th>
<th>Label</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proliferating cell nuclear antigen (PCNA)</td>
<td>Microwave with citrate buffer<sup><xref ref-type="table-fn" rid="table-fn1-0192623311436185">a</xref></sup>
</td>
<td>Normal donkey serum<sup><xref ref-type="table-fn" rid="table-fn3-0192623311436185">c</xref></sup>
</td>
<td>Rabbit polyclonal anti-PCNA<sup><xref ref-type="table-fn" rid="table-fn5-0192623311436185">e</xref></sup> (1:100)</td>
<td>Normal rabbit serum<sup><xref ref-type="table-fn" rid="table-fn3-0192623311436185">c</xref></sup>
</td>
<td>Biotin-conjugated donkey anti-rabbit IgG<sup><xref ref-type="table-fn" rid="table-fn3-0192623311436185">c</xref></sup> (1:1000)</td>
<td>Vectastain Standard Elite Label<sup><xref ref-type="table-fn" rid="table-fn4-0192623311436185">d</xref></sup>
</td>
<td>Storkel et al. 1993</td>
</tr>
<tr>
<td>Cyclin-D1</td>
<td>Decloaker with EDTA<sup><xref ref-type="table-fn" rid="table-fn1-0192623311436185">a</xref></sup>
</td>
<td>Vectastain Rabbit Elite Kit<sup><xref ref-type="table-fn" rid="table-fn4-0192623311436185">d</xref></sup>
</td>
<td>Rabbit monoclonal anti-cyclin D1<sup><xref ref-type="table-fn" rid="table-fn7-0192623311436185">g</xref></sup> (1:25)</td>
<td>Normal rabbit serum<sup><xref ref-type="table-fn" rid="table-fn3-0192623311436185">c</xref></sup>
</td>
<td>Vectastain Rabbit Elite Kit<sup><xref ref-type="table-fn" rid="table-fn4-0192623311436185">d</xref></sup>
</td>
<td>Vectastain Rabbit Elite Kit<sup><xref ref-type="table-fn" rid="table-fn4-0192623311436185">d</xref></sup>
</td>
<td>Schoelch et al. 1999</td>
</tr>
<tr>
<td>Beta-catenin</td>
<td>CC1 Solution<sup><xref ref-type="table-fn" rid="table-fn2-0192623311436185">b</xref></sup>
</td>
<td>OmniMap Anti-rabbit Polymer Kit<sup><xref ref-type="table-fn" rid="table-fn2-0192623311436185">b</xref></sup>
</td>
<td>Rabbit polyclonal anti-beta catenin<sup><xref ref-type="table-fn" rid="table-fn5-0192623311436185">e</xref></sup> (1:500)</td>
<td>Normal rabbit serum<sup><xref ref-type="table-fn" rid="table-fn3-0192623311436185">c</xref></sup>
</td>
<td>OmniMap Anti-rabbit Polymer Kit<sup><xref ref-type="table-fn" rid="table-fn2-0192623311436185">b</xref></sup>
</td>
<td>OmniMap Anti-rabbit Polymer Kit<sup><xref ref-type="table-fn" rid="table-fn2-0192623311436185">b</xref></sup>
</td>
<td>
<xref ref-type="bibr" rid="bibr2-0192623311436185">Bagutti et al. 1998</xref>; Bankfalvi et al. 2002</td>
</tr>
<tr>
<td>Mammary serine protease inhibitor (maspin)</td>
<td>Microwave with citrate buffer<sup><xref ref-type="table-fn" rid="table-fn1-0192623311436185">a</xref></sup>
</td>
<td>Normal donkey serum<sup><xref ref-type="table-fn" rid="table-fn3-0192623311436185">c</xref></sup>
</td>
<td>Rabbit polyclonal anti-maspin<sup><xref ref-type="table-fn" rid="table-fn5-0192623311436185">e</xref></sup> (1:50)</td>
<td>Normal rabbit serum<sup><xref ref-type="table-fn" rid="table-fn3-0192623311436185">c</xref></sup>
</td>
<td>Biotin-conjugated donkey anti-rabbit IgG<sup><xref ref-type="table-fn" rid="table-fn3-0192623311436185">c</xref></sup> (1:500)</td>
<td>Vectastain Standard Elite Label<sup><xref ref-type="table-fn" rid="table-fn4-0192623311436185">d</xref></sup>
</td>
<td>Vered et al. 2009a</td>
</tr>
<tr>
<td>α-Smooth muscle actin (SMA)</td>
<td>Decloaker with citrate buffer<sup><xref ref-type="table-fn" rid="table-fn1-0192623311436185">a</xref></sup>
</td>
<td>Vectastain Rabbit Elite Kit<sup><xref ref-type="table-fn" rid="table-fn4-0192623311436185">d</xref></sup>
</td>
<td>Rabbit polyclonal anti-SMA<sup><xref ref-type="table-fn" rid="table-fn6-0192623311436185">f</xref></sup> (1:500)</td>
<td>Normal rabbit serum<sup><xref ref-type="table-fn" rid="table-fn3-0192623311436185">c</xref></sup>
</td>
<td>Vectastain Rabbit Elite Kit<sup><xref ref-type="table-fn" rid="table-fn4-0192623311436185">d</xref></sup>
</td>
<td>Vectastain Rabbit Elite Kit<sup><xref ref-type="table-fn" rid="table-fn4-0192623311436185">d</xref></sup>
</td>
<td>Lewis et al. 2004; Vered et al. 2009b</td>
</tr>
<tr>
<td>osteonectin/ Cystine-rich acidic secreted protein (SPARC)</td>
<td>Decloaker with citrate buffer<sup><xref ref-type="table-fn" rid="table-fn1-0192623311436185">a</xref></sup>
</td>
<td>Normal horse serum<sup><xref ref-type="table-fn" rid="table-fn3-0192623311436185">c</xref></sup>
</td>
<td>Mouse Monoclonal anti-SPARC<sup><xref ref-type="table-fn" rid="table-fn5-0192623311436185">e</xref></sup> (1:25)</td>
<td>Mouse IgG1<sup><xref ref-type="table-fn" rid="table-fn8-0192623311436185">h</xref></sup>
</td>
<td>Biotinylated horse anti- mouse IgG<sup><xref ref-type="table-fn" rid="table-fn4-0192623311436185">d</xref></sup> (1:1,000)</td>
<td>Vectastain Standard Elite Label<sup><xref ref-type="table-fn" rid="table-fn4-0192623311436185">d</xref></sup>
</td>
<td>Chin et al. 2005; Mendez et al. 2002</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0192623311436185">
<p>
<sup>a</sup>Biocare Medical, Walnut Creek, CA</p>
</fn>
<fn id="table-fn2-0192623311436185">
<p>
<sup>b</sup>Ventana Medical Systems, Tuscon, AZ</p>
</fn>
<fn id="table-fn3-0192623311436185">
<p>
<sup>c</sup>Jackson Immunoresearch, West Grove, PA</p>
</fn>
<fn id="table-fn4-0192623311436185">
<p>
<sup>d</sup>Vector Laboratories, Burlingame, CA</p>
</fn>
<fn id="table-fn5-0192623311436185">
<p>
<sup>e</sup>Santa Cruz Biotechnology, Santa Cruz, CA</p>
</fn>
<fn id="table-fn6-0192623311436185">
<p>
<sup>f</sup>Abcam, Cambridge, MA</p>
</fn>
<fn id="table-fn7-0192623311436185">
<p>
<sup>g</sup>Cell Marque, Rocklin, CA</p>
</fn>
<fn id="table-fn8-0192623311436185">
<p>
<sup>h</sup>BD Biosciences, San Jose, CA</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>For the SPARC and SMA antibodies, antigen retrieval was carried out using a decloaking chamber and citrate buffer pH 6.0 solution. Cyclin D1 staining also required the decloaker, but EDTA pH 8.5 was used as the retrieval solution. Retrieval for both the maspin and PCNA markers was performed using a microwave with citrate buffer solution. After antigen retrieval, nonspecific sites were blocked using normal sera matching the host species of the secondary antibody. The tissues were then incubated with the various primary antibodies at these specified dilutions: SPARC, 1:25; maspin, 1:50; SMA, 1:500; cyclin D1, 1:25; and PCNA, 1:100. All antibodies were incubated at room temperature for sixty minutes except SMA, which had a thirty-minute incubation. Biotin-conjugated donkey anti-rabbit secondary was applied to the tissues for the PCNA and maspin stains at 1:1,000 and 1:500, respectively, for thirty minutes. A biotinylated horse anti-mouse secondary was also used for the SPARC staining at a 1:500 dilution for thirty minutes. After these secondary incubations, the slides were treated with the Vectastain Elite ABC Standard Kit for thirty minutes. For SMA and cyclin D1, sections were incubated with Vectastain Elite ABC Rabbit IgG Kit (Vector Laboratories, Burlingame, CA). The antigen of interest was visualized using 3-diaminobenzidine (DAB) chromagen. After counterstaining with hematoxylin, all sections were dehydrated through graded ethanol, cleared in xylene, and coverslipped. For negative controls, the antibody was replaced with a nonimmune serum diluted to match the protein concentration of the respective antibody.</p>
</sec>
<sec id="section8-0192623311436185">
<title>Assessment of the Immunostains</title>
<p>Assessment of the expression of the epithelial-related markers within the oral lining epithelium (GSH and control) was performed separately for the basal, suprabasal, and upper layers. Similarly, in the CKH lesions, the cystic epithelium was divided into the basal, suprabasal, and upper layer, where the latter referred to the luminal layers. In regard to SCC, assessment was done in the tumor at the front of invasion versus its more superficial areas.</p>
<p>Staining, assessed according to the extent of the positively stained cells, was classified as (–), no staining; (+), 1%–10% cells positively stained; (++), 11%–50%; and (+++), &gt; 50% positive cells. Proliferating cell nuclear antigen and cyclin D1 were assessed as nuclear stainings. In regard to β-catenin, only membranous staining was considered positive. Maspin was assessed in both the cytoplasmic and nuclear compartments. Expression of α-SMA and SPARC was assessed as cytoplasmic staining in cells adjacent to the oral lining or cystic epithelia or close to the tumor.</p>
</sec>
<sec id="section9-0192623311436185">
<title>Statistical Analysis</title>
<p>The incidences of microscopic lesions were evaluated statistically by the poly-3 test (<xref ref-type="bibr" rid="bibr3-0192623311436185">Bailer and Portier 1988</xref>; <xref ref-type="bibr" rid="bibr50-0192623311436185">Portier and Bailer 1989</xref>), which makes adjustments for survival differences among groups. Severity scores were compared among dose groups using the Kruskal-Wallis analysis of variance for an overall comparison, and using Mann-Whitney tests to compare each dose group to the control group (<xref ref-type="bibr" rid="bibr31-0192623311436185">Hollander and Wolfe 1973</xref>).</p>
</sec>
</sec>
<sec id="section10-0192623311436185">
<title>Results</title>
<sec id="section11-0192623311436185">
<title>Microscopic Evaluation of the Gingivae</title>
<p>The frequencies of the different types of gingival lesions for each dose group of animals are summarized in <xref ref-type="table" rid="table2-0192623311436185">Table 2</xref>. All lesions were confined to nasal section level III.</p>
<table-wrap id="table2-0192623311436185" position="float">
<label>Table 2.</label>
<caption>
<p>Incidence and Mean Severity (in parentheses) of Neoplasms and Non-neoplastic Lesions of the Oral Cavity in Rats in the Two-Year Gavage Study of TCAB</p>
</caption>
<graphic alternate-form-of="table2-0192623311436185" xlink:href="10.1177_0192623311436185-table2.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Vehicle</th>
<th>10 mg/kg</th>
<th>30 mg/kg</th>
<th>100 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of animals necropsied</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td colspan="5">Male</td>
</tr>
<tr>
<td> Gingival hyperplasia, squamous</td>
<td>2 (1.0)</td>
<td>21** (1.7)</td>
<td>24** (1.8)</td>
<td>31** (1.8)</td>
</tr>
<tr>
<td> Gingival, hyperplasia, cystic keratinizing</td>
<td>0</td>
<td>4* (1.1)</td>
<td>18** (0.9)</td>
<td>11** (1.4)</td>
</tr>
<tr>
<td colspan="5"> Gingival, squamous cell carcinoma</td>
</tr>
<tr>
<td>  Overall rate<sup><xref ref-type="table-fn" rid="table-fn11-0192623311436185">a</xref></sup>
</td>
<td>1/50 (2%)</td>
<td>5/50 (10%)</td>
<td>4/50 (8%)</td>
<td>5/50 (10%)</td>
</tr>
<tr>
<td>  Adjusted rate<sup><xref ref-type="table-fn" rid="table-fn12-0192623311436185">b</xref></sup>
</td>
<td>2.5%</td>
<td>16.7%</td>
<td>14.5%</td>
<td>18.8%</td>
</tr>
<tr>
<td>  Poly-3 test<sup><xref ref-type="table-fn" rid="table-fn13-0192623311436185">c</xref></sup>
</td>
<td>
<italic>p</italic> = 0.065</td>
<td>
<italic>p</italic> = 0.046</td>
<td>
<italic>p</italic> = 0.085</td>
<td>
<italic>p</italic> = 0.033</td>
</tr>
<tr>
<td>Female</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Gingival hyperplasia, squamous</td>
<td>0</td>
<td>8** (1.8)</td>
<td>24** (1.4)</td>
<td>24** (1.4)</td>
</tr>
<tr>
<td> Gingival, hyperplasia, cystic keratinizing</td>
<td>0</td>
<td>4 (1.0)</td>
<td>9** (1.1)</td>
<td>13** (1.3)</td>
</tr>
<tr>
<td colspan="5"> Gingival, squamous cell carcinoma</td>
</tr>
<tr>
<td>  Overall rate</td>
<td>0/50 (0%)</td>
<td>0/50 (0%)</td>
<td>4/50 (8%)</td>
<td>6/50 (12%)</td>
</tr>
<tr>
<td>  Adjusted rate</td>
<td>0.0%</td>
<td>0.0%</td>
<td>10.6%</td>
<td>15.4%</td>
</tr>
<tr>
<td>  Poly-3 test</td>
<td>
<italic>p</italic> = 0.002</td>
<td align="center">–</td>
<td>
<italic>p</italic> = 0.055</td>
<td>
<italic>p</italic> = 0.015</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0192623311436185">
<p>* Significantly different (<italic>p</italic> ≤ .05) from the vehicle control group by Poly-3 test.</p>
</fn>
<fn id="table-fn10-0192623311436185">
<p>** <italic>p</italic> ≤ .01.</p>
</fn>
<fn id="table-fn11-0192623311436185">
<p>
<sup>a</sup> Number of animals with neoplasm per number of animals necropsied.</p>
</fn>
<fn id="table-fn12-0192623311436185">
<p>
<sup>b</sup> Poly-3 estimated neoplasm incidence after adjustment for intercurrent mortality.</p>
</fn>
<fn id="table-fn13-0192623311436185">
<p>
<sup>c</sup> Beneath the vehicle control incidence are the <italic>p</italic> values associated with the trend test. Beneath the dosed group incidence are the <italic>p</italic> values corresponding to pairwise comparison between the vehicle controls and that dosed group. The Poly-3 test accounts for differential mortality in animals that did not reach terminal sacrifice.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Increased incidence of gingival SCC, single or multiple, was noted in both sexes treated with 30 and 100 mg/kg, and in the males treated with the 10 mg/kg compared to control. The highest incidence was seen in the females treated with the 100 mg/kg compared to control. Generally, a dose-related increased incidence of gingival squamous cell hyperplasia and gingival CKH was noted in all treated groups of both sexes, except for the incidence of CKH in the high-dose males.</p>
<p>The following histopathological descriptions summarize findings from all study groups. Squamous hyperplasia occurred in the stratified squamous epithelium of the gingival oral mucosa adjacent to the molar teeth in nasal section III, and it consisted of varying degrees of thickening of the epithelium, generally with the formation of epithelial rete ridges that extended into the underlying connective tissue. Minimal lesions, located directly adjacent to the molar teeth, consisted of slight thickening of the epithelium. As severity increased, the epithelium became thicker, usually demonstrating formation of multiple papillary projections, accompanied by abundant keratin accumulation and prominent rete ridges. In some of the more severe cases of hyperplasia, the hyperplastic epithelium formed prominent invaginations into the underlying palate, displacing normal tissue, thus somewhat resembling invasive lesions (<xref ref-type="fig" rid="fig1-0192623311436185">Figure 1</xref>). It was noted in some sections containing the root of a molar tooth (i.e., the periodontal ligament) that the hyperplastic epithelium tended to grow down along the root.</p>
<fig id="fig1-0192623311436185" position="float">
<label>Figure 1.</label>
<caption>
<p>Gingival lesions of 3,3′,4,4′-tetrachloroazobenzene (TCAB)–treated rats. (A) Oral cavity mucosa at nasal section III (at the level of the molars) in a male Harlan Sprague-Dawley rat administered 100 mk/kg TCAB by gavage for two years. Note the presence of gingival squamous hyperplasia (arrows) and gingival cystic keratinizing hyperplasia (arrowheads). Hematoxylin and eosin. G, gingiva; MT, molar tooth; NP, nasopharynx. (B) Squamous cell carcinoma in the oral cavity mucosa at nasal section III (at the level of the molars) in a female Harlan Sprague-Dawley rat administered 100 mk/kg TCAB by gavage for two years. Note the irregular cords and clusters of stratified squamous epithelial cells that invade deeply into the underlying connective tissue (arrows). Hematoxylin and eosin.</p>
</caption>
<graphic xlink:href="10.1177_0192623311436185-fig1.tif"/>
</fig>
<p>Cystic keratinizing hyperplasia also occurred adjacent to the molar teeth in section III. It was characterized by variably sized cavities lined by stratified squamous epithelium and filled with keratin located deep to the oral surface. Minimal lesions consisted of one to a few small, ovoid cavities, lined by a thin layer of epithelium and containing small amounts of keratin, lying within the connective tissue of the palate a short distance below the oral lining epithelium. Some of these lesions occurred in isolation, whereas others occurred in association with diffuse hyperplastic lesions more typical of squamous hyperplasia and appeared to be arising from the more diffuse hyperplasia. As the severity of the cystic lesions increased, the size of the lumina and the depth of penetration into underlying tissues increased. In moderate to severe cases, the cystic structures penetrated deep into surrounding tissues, including into the nasal cavity, and into the soft tissues attached to the maxilla (<xref ref-type="fig" rid="fig1-0192623311436185">Figure 1A</xref>). The lining of more severe lesions often tended to have areas of irregular thickening and formed multiple, adjacent cystic structures, giving the lesion a multilocular appearance. Generally, a connection could be seen between the cystic structure and the overlying gingival oral mucosa, suggesting that the CKH may have arisen from squamous hyperplasia. In some cases of severe CKH with penetration into the nasal cavity, variably sized islands and keratin pearls of stratified squamous epithelium, embedded within dense fibrous tissue, were seen lying deep to the cystic structure and were considered indicative of invasion. These lesions were diagnosed as SCC.</p>
<p>Squamous cell carcinoma occurred within the oral mucosa adjacent to the molar tooth in nasal section III. It was characterized by irregular cords and clusters of stratified squamous epithelial cells that invaded deep into the underlying connective tissue, usually accompanied by abundant fibrous tissue proliferation (<xref ref-type="fig" rid="fig1-0192623311436185">Figure 1B</xref>).</p>
</sec>
<sec id="section12-0192623311436185">
<title>Immunohistochemical Stains</title>
<p>A summary of immunohistochemical stains is presented in <xref ref-type="table" rid="table3-0192623311436185">Table 3</xref>. All negative controls showed absence of staining (results not shown).</p>
<table-wrap id="table3-0192623311436185" position="float">
<label>Table 3.</label>
<caption>
<p>Immunohistochemical Expression of the Examined Markers According to the Various Diagnoses<sup><xref ref-type="table-fn" rid="table-fn14-0192623311436185">a</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table3-0192623311436185" xlink:href="10.1177_0192623311436185-table3.tif"/>
<table>
<thead>
<tr>
<th>Immunohistochemical marker</th>
<th>Normal</th>
<th>Gingival squamous hyperplasia</th>
<th>Gingival cystic keratinizing hyperplasia</th>
<th>Squamous cell carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of tissues</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Proliferating cell nuclear antigen </td>
<td>(++) basal layer (−) all other layers</td>
<td>(++) basal and suprabasal layers (−) upper layer</td>
<td>(++) basal layer (−) other layers</td>
<td>(+++) front of invasion; (++) superficial area</td>
</tr>
<tr>
<td>Cyclin-D1</td>
<td>(+) basal layer (−) all other layers</td>
<td>(++) basal and suprabasal layers (−) upper layer</td>
<td>(++) basal and suprabasal layers (−) upper layer</td>
<td>(+++) front of invasion; (++) superficial area</td>
</tr>
<tr>
<td>β-catenin</td>
<td>(+) – (++) basal layer (+++) suprabasal layer (+) – (++) upper layer</td>
<td>(++) basal and suprabasal layers (+) upper layer</td>
<td>(−) all layers </td>
<td>(−) front of invasion (+) superficial area</td>
</tr>
<tr>
<td>Mammary serine protease inhibitor (maspin)</td>
<td>(+++) all layers, cytoplasmic</td>
<td>(++) – (+++) all layers, cytoplasmic and also nuclear</td>
<td>(+) – (++), all layers, cytoplasmic and also nuclear</td>
<td>(−) – (+) all areas for both cytoplasmic and nuclear</td>
</tr>
<tr>
<td>α-Smooth muscle actin<sup><xref ref-type="table-fn" rid="table-fn15-0192623311436185">b</xref></sup>
</td>
<td>(−)</td>
<td>(−)</td>
<td>(−) – (+) all areas</td>
<td>(−) – (+) all areas</td>
</tr>
<tr>
<td>Cystine-rich acidic secreted protein (SPARC)/osteonectin<sup><xref ref-type="table-fn" rid="table-fn16-0192623311436185">c</xref></sup>
</td>
<td>(−)</td>
<td>(−) – (+) adjacent to the lining epithelium</td>
<td>(−) – (+) adjacent to the cystic epithelium</td>
<td>(+) all areas</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn14-0192623311436185">
<p>
<sup>a</sup> (−) no staining; (+) 1% - 10% stained cells; (++) 11% - 50% stained cells; (+++) &gt;50% stained cells]</p>
</fn>
<fn id="table-fn15-0192623311436185">
<p>
<sup>b</sup> Blood vessel walls served as control.</p>
</fn>
<fn id="table-fn16-0192623311436185">
<p>
<sup>c</sup> Cells within tumor microenvironment.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section13-0192623311436185">
<title>Proliferating cell nuclear antigen</title>
<p>In normal epithelium, expression was seen in scattered basal cells of the lining epithelium of the gingival papillae (<xref ref-type="fig" rid="fig2-0192623311436185">Figure 2A</xref> and <xref ref-type="fig" rid="fig2-0192623311436185">2B</xref>). In GSH, expression of PCNA was frequent and involved both basal and suprabasal layers (<xref ref-type="fig" rid="fig2-0192623311436185">Figure 2C</xref> and <xref ref-type="fig" rid="fig2-0192623311436185">2D</xref>). In CKH, expression was mainly in the basal layer (<xref ref-type="fig" rid="fig2-0192623311436185">Figure 2E</xref> and <xref ref-type="fig" rid="fig2-0192623311436185">2F</xref>). In SCC, expression was most evident at the front of invasion (<xref ref-type="fig" rid="fig2-0192623311436185">Figure 2G</xref> and <xref ref-type="fig" rid="fig2-0192623311436185">2H</xref>).</p>
<fig id="fig2-0192623311436185" position="float">
<label>Figure 2.</label>
<caption>
<p>Proliferating cell nuclear antigen (PCNA) immunohistochemical profile of 3,3′,4,4′-tetrachloroazobenzene (TCAB)–induced gingival lesions. (A). Epithelium lining the gingival papilla from a control male rat. Note the PCNA positive staining of the basal cells (black arrows). There is mild gingivitis in the mucosa close to the molar tooth, indicated by PCNA-positive inflammatory cells (green arrows); ×100. (B) Epithelium lining the gingival papilla from a control male rat. Magnification of a region from (A), further showing the PCNA-positively stained basal cells (arrows); ×200. (C) Gingival hyperplasia (moderate) from a high-dose TCAB–treated male rat. Note the strong, continuous staining within cells located at the basal and suprabasal layers (arrows); ×100. (D) Gingival hyperplasia (moderate) from a high-dose TCAB–treated male rat. A magnified area of (C), showing the strong positively stained nuclei within cells located at the basal and suprabasal layers (arrows); ×200. (E) Cystic keratinizing gingival hyperplasia from a high-dose TCAB–treated male rat. Note a segment of the cystic epithelium demonstrating strong positively stained nuclei within basally located cells (arrows). The adjacent segment of cystic epithelium is negative to PCNA (green arrow); × 40. (F) Cystic keratinizing gingival hyperplasia from a high-dose TCAB–treated male rat. Note a segment of the cystic epithelium demonstrating strong positively stained nuclei within cells located at the basal layer (black arrows). Note the higher intensity of staining comparing to the control (A and B); × 200. (G) Gingival squamous cell carcinoma from a high-dose TCAB–treated male rat. Note strong positively stained nuclei at the periphery of the tumor islands, which are most evident in the invading islands (arrows); ×40. (H) Gingival squamous cell carcinoma from a high-dose TCAB–treated male rat. Higher magnification from (G), lower right corner, demonstrating strongly positive nuclei, which are most evident at the invasion front (arrows); ×200.</p>
</caption>
<graphic xlink:href="10.1177_0192623311436185-fig2.tif"/>
</fig>
</sec>
<sec id="section14-0192623311436185">
<title>Cyclin D1</title>
<p>In normal gingival epithelium, only a minority of basal cells showed positively stained nuclei (<xref ref-type="fig" rid="fig3-0192623311436185">Figure 3A</xref> and <xref ref-type="fig" rid="fig3-0192623311436185">3B</xref>). In GSH, expression of cyclin D1 was frequent and involved both the basal and suprabasal layers (<xref ref-type="fig" rid="fig3-0192623311436185">Figure 3C and 3D</xref>). CKH demonstrated a similar pattern of expression as GSH (<xref ref-type="fig" rid="fig3-0192623311436185">Figure 3E</xref> and <xref ref-type="fig" rid="fig3-0192623311436185">3F</xref>). Squamous cell carcinoma showed high expression, especially in the invading and less differentiated areas (<xref ref-type="fig" rid="fig3-0192623311436185">Figure 3G</xref> and 3H).</p>
<fig id="fig3-0192623311436185" position="float">
<label>Figure 3.</label>
<caption>
<p>Cyclin D1 immunohistochemical profile of TCAB-induced gingival lesions. (A) Epithelium lining the gingival papilla from a control male rat. There are only sparse faintly cyclin D1–stained nuclei within the basal layer (arrow); ×200. (B) Epithelium lining the gingival papilla from a control male rat. Magnification of the bottom region of (A), showing a few faintly stained nuclei within the basal layer (arrows); ×400. (C) Gingival hyperplasia (moderate) from a high-dose TCAB–treated male rat. Note strong positively stained nuclei within cells located at the basal and suprabasal layers (arrows); ×100. (D) Gingival hyperplasia (moderate) from a high-dose TCAB–treated male rat. Magnification of the upper left region from (C) showing the strong positively stained nuclei within cells located at the basal and suprabasal layers (arrows); ×200. (E) Cystic keratinizing gingival hyperplasia from a high-dose TCAB–treated male rat. Note continuous and strong nuclear staining within cells located at the basal and suprabasal layers (arrows); ×100. (F) Cystic keratininzing gingival hyperplasia from a high-dose TCAB–treated male rat. Magnification of an area (bottom right) from (E) further showing the strong positively stained nuclei within cells located at the basal and suprabasal layers (arrows); ×400. (G) Gingival squamous cell carcinoma from a high-dose TCAB–treated male rat. Note strongly stained nuclei, which are most evident in the invading islands (arrows); ×200. (H) Gingival squamous cell carcinoma from a high-dose TCAB–treated male rat. Magnification of the top region from (G), which emphasizes the strong and frequent nuclear staining of the invading islands (arrows); ×400.</p>
</caption>
<graphic xlink:href="10.1177_0192623311436185-fig3.tif"/>
</fig>
</sec>
<sec id="section15-0192623311436185">
<title>β-Catenin</title>
<p>In the normal gingiva, membranous expression was mainly in the suprabasal and basal side of the upper layer (<xref ref-type="fig" rid="fig4-0192623311436185">Figure 4A</xref>). Gingival squamous hyperplasia had a similar pattern of expression as the normal gingiva (<xref ref-type="fig" rid="fig4-0192623311436185">Figure 4B</xref> and <xref ref-type="fig" rid="fig4-0192623311436185">4C</xref>). In superficially located CKH, membranous expression was evident throughout the epithelium (<xref ref-type="fig" rid="fig4-0192623311436185">Figure 4D</xref>), whereas in deeper located CKH, there was overall loss of membranous β-catenin (<xref ref-type="fig" rid="fig4-0192623311436185">Figure 4E</xref>). In SCC, membranous expression was gradually lost as the tumor invaded, and at the invasion front, no membranous staining was present (<xref ref-type="fig" rid="fig4-0192623311436185">Figure 4F</xref> and <xref ref-type="fig" rid="fig4-0192623311436185">4G</xref>).</p>
<fig id="fig4-0192623311436185" position="float">
<label>Figure 4.</label>
<caption>
<p>β-catenin immunohistochemical profile of 3,3′,4,4′-tetrachloroazobenzene (TCAB)–induced gingival lesions. (A) Lining epithelium of the gingival papilla from a control male rat showing extensive normal membranous β-catenin staining in the spinous layer (arrows); ×400. (B) Gingival hyperplasia (moderate) from a high-dose TCAB–treated male rat. Note that there is membranous staining in the entire width of the epithelium (black arrows). However, some cytoplasmatic staining is also observed, especially within cells from the more basal layers (green arrows); ×400. C. Gingival hyperplasia (moderate) from a high-dose TCAB–treated male rat. In this example, cytoplasmatic staining is predominant (green arrows) over the membranous staining, which is mainly constrained to cells from the upper epithelium (black arrows); ×400. (D) Cystic keratinizing gingival hyperplasia from a high-dose TCAB–treated male rat. There is membranous staining throughout the width of the cystic epithelium (arrows); ×400. (E) Cystic keratinizing gingival hyperplasia from a high-dose TCAB–treated male rat. Another area from the cystic lesion presented in (D) showing lack of membranous staining (arrows); ×400. (F) Gingival squamous cell carcinoma from a high-dose TCAB–treated male rat. Overall, there is loss of membranous staining in the deep infiltrating invasive islands with only some residual, weak cytoplasmic staining (arrows); ×200. (G) Higher magnification of a region in (F) further demonstrating loss of membranous staining (arrows); ×400.</p>
</caption>
<graphic xlink:href="10.1177_0192623311436185-fig4.tif"/>
</fig>
</sec>
<sec id="section16-0192623311436185">
<title>Maspin</title>
<p>In the normal gingiva, maspin was expressed in all layers of the epithelium as a homogenous membranous - cytoplasmatic staining (<xref ref-type="fig" rid="fig5-0192623311436185">Figure 5A</xref>). In GSH, expression was observed also at a nuclear level (<xref ref-type="fig" rid="fig5-0192623311436185">Figure 5B</xref> and <xref ref-type="fig" rid="fig5-0192623311436185">5C</xref>). In contrast, in CKH, staining was gradually lost (<xref ref-type="fig" rid="fig5-0192623311436185">Figure 5D</xref> and <xref ref-type="fig" rid="fig5-0192623311436185">5E</xref>), and in SCC, expression of maspin decreased in parallel to the depth of invasion (<xref ref-type="fig" rid="fig5-0192623311436185">Figure 5F</xref> and <xref ref-type="fig" rid="fig5-0192623311436185">5G</xref>).</p>
<fig id="fig5-0192623311436185" position="float">
<label>Figure 5.</label>
<caption>
<p>Maspin immunohistochemical profile of 3,3′,4,4′-tetrachloroazobenzene (TCAB)–induced gingival lesions. (A) Epithelium lining the gingival papilla from a control male rat. The staining is homogenous in all layers, and mostly membranous and cytoplasmatic (arrows); ×400. (B) Gingival hyperplasia (moderate) from a high-dose TCAB–treated male rat. The membranous/cytoplasmatic staining is usually preserved, however, there are areas almost lacking this pattern of staining (arrows). Concurrently, several cells with nuclear staining can be observed (arrowheads); ×100. (C) Gingival hyperplasia (moderate) from a high-dose TCAB–treated male rat. Note the cytoplasmic staining, which is usually preserved. In addition, many of the nuclei in this area are also positively stained (arrows); ×100. (D) Cystic keratinizing gingival hyperplasia from a high-dose TCAB–treated male rat. Note the partial loss of staining (arrows), which is more pronounced in deeper and invasive regions; ×100. (E) Cystic keratinizing gingival hyperplasia from a high-dose TCAB–treated male rat. A magnification of a region from (D), showing the transition between strong membranous and nuclear staining (red arrows) to an area almost devoid of any staining (black arrow); ×400. (F) Gingival squamous cell carcinoma from a high-dose TCAB–treated male rat. Note the partial loss of staining in the deepest invading neoplastic islands (arrows). (G) Gingival squamous cell carcinoma from a high-dose TCAB–treated male rat. A magnified area from Figure F, showing partial loss of staining (black arrows, left side) versus strong cytoplamic and nuclear staining (red arrows, right side); ×100.</p>
</caption>
<graphic xlink:href="10.1177_0192623311436185-fig5.tif"/>
</fig>
</sec>
<sec id="section17-0192623311436185">
<title>α-Smooth muscle actin</title>
<p>In normal and GSH lesions, expression was confined to the smooth muscle cells located within the blood vessel walls (<xref ref-type="fig" rid="fig6-0192623311436185">Figure 6A</xref>). In CKH (<xref ref-type="fig" rid="fig6-0192623311436185">Figure 6B</xref> and <xref ref-type="fig" rid="fig6-0192623311436185">6C</xref>) and SCC (<xref ref-type="fig" rid="fig6-0192623311436185">Figure 6D</xref>), sporadic, spindle-shaped, positively stained stromal cells were observed running in parallel to the cystic epithelium and tumor islands, respectively.</p>
<fig id="fig6-0192623311436185" position="float">
<label>Figure 6.</label>
<caption>
<p>α-Smooth muscle actin immunohistochemical profile of 3,3′,4,4′-tetrachloroazobenzene (TCAB)–induced gingival lesions. (A) Gingival papilla from a control male rat. The smooth muscle cells located within the blood vessel walls (arrows) are αSMA positive. There are no positive stromal cells close to the lining gingival epithelium; ×200. (B,C) Cystic keratinizing gingival hyperplasia from a high-dose TCAB -treated male rat. Note sporadic, spindle-shaped, a SMA-positive stromal cells, usually located adjacent to the cystic epithelium (arrows); ×400. (D) Gingival squamous cell carcinoma from a high-dose TCAB–treated male rat. Note sporadic, spindle-shaped, αSMA-positive stromal cells usually located adjacent to the tumor (arrows); ×400.</p>
</caption>
<graphic xlink:href="10.1177_0192623311436185-fig6.tif"/>
</fig>
</sec>
<sec id="section18-0192623311436185">
<title>Cystine-rich acidic secreted protein /osteonectin</title>
<p>No expression was detected in normal gingiva, except for sporadic stromal cells in areas of minimal gingivitis. In CKH (<xref ref-type="fig" rid="fig7-0192623311436185">Figure 7A</xref>) and GSH (<xref ref-type="fig" rid="fig7-0192623311436185">Figure 7B</xref>), sporadic positive stromal cells located close to the hyperplastic epithelium were seen.</p>
<fig id="fig7-0192623311436185" position="float">
<label>Figure 7.</label>
<caption>
<p>Osteonectin/cystine-rich acidic secreted protein (SPARC) immunohistochemical profile of 3,3′,4,4′-tetrachloroazobenzene (TCAB)–induced gingival lesions. (A) Stromal SPARC-positive cells (arrows) located adjacent to reactive bone, in close proximity to cystic keratinizing hyperplasia from a high-dose TCAB–treated male rat. (B) Gingival hyperplasia from a high-dose TCAB–treated male rat. Note the SPARC-positive stromal cells adjacent to the epithelial islands (arrows); ×400.</p>
</caption>
<graphic xlink:href="10.1177_0192623311436185-fig7.tif"/>
</fig>
</sec>
</sec>
</sec>
<sec id="section19-0192623311436185">
<title>Discussion</title>
<p>Recently, the effects of chronic exposure of rats to dioxin and dioxin-like compounds (DLCs) have been reported in detail following the two-year chronic gavage studies performed by the National Toxicology Program with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD); 3,3′,4,4′,5-pentachlorobiphenyl (PCB126); 2,3,4,7,8-pentachloro-dibenzofuran (PeCDF); 2,2′,4,4′,5,5′-hexachlorobiphenyl (PCB153); the Toxic Equivalency Factor (TEF) tertiary mixture of TCDD, PCB126, and PeCDF; and the binary mixtures of PCB126 and 153 and PCB126 and 2,3′,4,4′,5-pentachlorobiphenyl (PCB118; <xref ref-type="bibr" rid="bibr80-0192623311436185">Yoshizawa et al. 2005</xref>). In these experiments, the incidence of gingival squamous hyperplasia was significantly increased following exposure to the tested compounds, and exposure to TCDD, PCB126, and the mixture of PCB126 and 153 led to a significant increase in gingival SCC incidence (<xref ref-type="bibr" rid="bibr80-0192623311436185">Yoshizawa et al. 2005</xref>). The effect of DLCs on the oral cavity has been demonstrated before in a number of reports in humans and animals (<xref ref-type="bibr" rid="bibr80-0192623311436185">Yoshizawa et al. 2005</xref>). For example, in humans, elongation of the depth of periodontal pockets and gingival pigmentation was observed following exposure to PCBs and PeCDFs (<xref ref-type="bibr" rid="bibr28-0192623311436185">Hashiguchi et al. 1995</xref>). In monkeys, an array of oral changes was observed, including GSH, hyperkeratosis, dyskeratosis, keratocystic formation, squamous metaplasia of the ameloblast surrounding unerupted teeth, and/or hyperpigmentation (<xref ref-type="bibr" rid="bibr27-0192623311436185">Hashiguchi et al. 1983</xref>; <xref ref-type="bibr" rid="bibr26-0192623311436185">Hashiguchi et al. 1987</xref>; <xref ref-type="bibr" rid="bibr41-0192623311436185">McNulty 1985</xref>; <xref ref-type="bibr" rid="bibr60-0192623311436185">Tryphonas et al. 1986</xref>; <xref ref-type="bibr" rid="bibr77-0192623311436185">Yoshihara et al. 1979</xref>). However, the oral carcinogenicity properties of DLCs were not demonstrated before the current long-term studies conducted by the NTP (<xref ref-type="bibr" rid="bibr80-0192623311436185">Yoshizawa et al. 2005</xref>).</p>
<p>Here we report that TCAB, an additional DLC, may also predispose to gingival SCC. In addition, we report for the first time the development of a new type of DLC-associated gingival lesion, cystic keratinizing hyperplasia (CKH), which is characterized by variably sized cavities lined by stratified squamous epithelium and filled with keratin located deep to the overlying gingival epithelium. It is not clear why TCAB was the only DLC to cause CKH in the gingivae. However, our studies with different DLCs suggest that the range of neoplastic and non-neoplastic lesions seen in the same organ may vary among the DLC compounds. For example, in the reproductive system, uterine SCC was caused only by TCDD and the binary mixture of PCB126 and 153, whereas no change was noted with all other DLCs (<xref ref-type="bibr" rid="bibr78-0192623311436185">Yoshizawa et al. 2009a</xref>). This finding suggests that more than one mechanism is involved in DLC-induced carcinogenesis in rats, including in the gingivae. Additionally, some of the carcinogenic effects of TCAB might be induced by one or more of its dichloroaniline metabolites (<xref ref-type="bibr" rid="bibr46-0192623311436185">Pillai et al. 1996</xref>), and not directly by TCAB.</p>
<p>3,3′,4,4′-Tetrachloroazobenzene, like other DLCs, binds to its cytosolic aryl hydrocarbon receptor (AhR; <xref ref-type="bibr" rid="bibr43-0192623311436185">NTP 2009</xref>). The latter dissociates from the chaperones, dimerizes with AhR nuclear translocator, and ultimately translocates into the nucleus, where it induces changes in gene transcription (<xref ref-type="bibr" rid="bibr40-0192623311436185">Martinez et al. 2002</xref>). Indeed, the AhR has previously been shown to be expressed in oral tissues, including the molar teeth buds and palatal epithelial cells, and its activation has been shown to change epithelial cell differentiation and proliferation (<xref ref-type="bibr" rid="bibr80-0192623311436185">Yoshizawa et al. 2005</xref>). It should be noted, however, that there are many different factors that can influence the effects of various DLCs by altering the responsiveness of downstream pathways (<xref ref-type="bibr" rid="bibr24-0192623311436185">Harper et al. 2006</xref>). Therefore, although presumably all DLCs act by binding to the AhR, it is hard to predict the end effect of each DLC as a result of this complex set of mediators. This is especially the case when considering the recently gained knowledge on the AhR-mediated activities that are not mediated by the canonical dioxin response element–dependent gene expression (<xref ref-type="bibr" rid="bibr42-0192623311436185">Murray et al. 2010</xref>). 3,3′,4,4′-Tetrachloroazobenzene, delivered over a long period of time, appears to exert a hyperplastic and neoplastic effect on the lining epithelium of the gingivae, in particular in the region of the maxillary molars. There are several possible explanations for the increased sensitivity of this region to TCAB administered by gavage (<xref ref-type="bibr" rid="bibr80-0192623311436185">Yoshizawa et al. 2005</xref>). The gingival epithelium, especially in the dento-gingival junction of molars, possesses a high mitotic activity (<xref ref-type="bibr" rid="bibr38-0192623311436185">Loe et al. 1972</xref>; <xref ref-type="bibr" rid="bibr53-0192623311436185">Shimono et al. 2003</xref>; <xref ref-type="bibr" rid="bibr69-0192623311436185">Watanabe et al. 2004</xref>). Together with its high metabolic activity (<xref ref-type="bibr" rid="bibr67-0192623311436185">Vondracek et al. 2001</xref>) and high rate of absorption (<xref ref-type="bibr" rid="bibr55-0192623311436185">Shojaei 1998</xref>), the molar gingival epithelium becomes a location that is very sensitive to xenobiotic effects. Another explanation can be based on the anatomy of this region. It can be assumed that a certain amount of the gavage containing the chemical agent repeatedly and persistently flows toward the posterior maxillary sulcus (vestibule), where it is kept in tight contact with the gingival epithelium, which in time reacts to the chronic irritation with a hyperplastic response. Furthermore, some of the chemical probably penetrates into the gingival sulcus, where it delivers a chronic stimulus to the junctional epithelium, which in time is translated into hyperplastic lesions that were observed to run along the tooth root. However, it is not likely that the lesions occur solely as a result of gavaging, because these types of tumors are rarely seen in vehicle control animals in other gavage studies. In male F344 rats, in which background tumor incidence is well established, the mean incidence of SCC seen in vehicle controls from corn oil gavage studies is 0.33% (range 0%–2%) which is similar to the mean background incidence for SCC for all routes of administration (http://ntp.niehs.nih.gov/ntpweb/index.cfm?objectid=92E705C7-F1F6-975E-72D23026B1645EB9<bold>
</bold>).</p>
<p>The TCAB model is partly similar to other animal models (rats and mice) in which the carcinogenic potential of different chemicals was tested, in particular 4-nitroquinoline 1-oxide (4NQO; <xref ref-type="bibr" rid="bibr14-0192623311436185">Dayan et al. 1997</xref>; <xref ref-type="bibr" rid="bibr32-0192623311436185">Kanojia and Vaidya 2006</xref>). This is a water-soluble carcinogen that, when administered in drinking water in very small concentrations for long periods of time, simulates the action of carcinogenic agents within the oral cavity of humans (e.g., tobacco smoke). In a time-dependent manner, under the action of 4NQO, a range of lesions develop on the animals’ tongues that are both morphologically and cytologically analogous to the precursor lesions seen in human patients, namely, hyperplasia and escalating dysplasia, which finally culminate in invading SCC (<xref ref-type="bibr" rid="bibr14-0192623311436185">Dayan et al. 1997</xref>; <xref ref-type="bibr" rid="bibr66-0192623311436185">Vered et al. 2005</xref>). This also may be the case with the DLCs / TCAB, where GSH is the earliest morphological type of lesion to be observed, CKH seems to be a more severe lesion in terms of penetration into the depth of the surrounding tissues than GSH, and SCC is the most invasive<bold>
</bold> lesion. However, there are several important differences between the 4NQO and TCAB animal models that basically lie in the mode of action of these agents. The 4NQO is metabolized to 4-hydroxyamino-quinoline-1-oxide (4HAQO), which in turn is known to be implicated in the formation of single and double DNA strand breaks (<xref ref-type="bibr" rid="bibr32-0192623311436185">Kanojia and Vaidya 2006</xref>). On the other hand, TCAB, as it is a nongenotoxic compound, does not induce direct DNA damage (<xref ref-type="bibr" rid="bibr40-0192623311436185">Martinez et al. 2002</xref>), unlike 4NQO. These differential mechanisms of action may provide an explanation of why at the cytological level the carcinoma precursor lesions (i.e., benign hyperplasia and dysplasia) produced by the 4NQO present not only morphological but also cytological abnormalities, whereas those caused by TCAB consist mainly of morphological changes without remarkable cytological atypia. Taken together, to the best of our knowledge, this is the first time that CKH and malignant epithelial lesions have been characterized for a nongenotoxic compound, that is, TCAB.</p>
<p>By employing a panel of epithelial markers related to the cell cycle and cellular differentiation status, we showed that changes in their expression in GSH was different from the control and that in CKH it was very similar to SCC. In general, we found that the carcinogenesis-associated immunohistochemical profile followed the morphological changes of increased extent of GSH and CKH and their depth of invasion, suggesting that they can be considered as lesions with potential for malignant transformation.</p>
<p>The pattern of expression of PCNA was more extensive in the GSH lesions compared to control and most remarkable in the SCCs, and in general, it followed that of cyclin-D1. Upon DNA damage signal and activation of p53, one of the G1-S controllers induced by p53 is GADD45 (<xref ref-type="bibr" rid="bibr25-0192623311436185">Hartl and Jones 2009</xref>). The latter forms a complex with PCNA that reduces the processivity of DNA polymerase with an outcome of slowing down DNA synthesis, allowing for DNA repair. 3,3′,4,4′-Tetrachloroazobenzene, through its receptor, AhR, has an inhibitory effect on the transcription activity of p53 (<xref ref-type="bibr" rid="bibr59-0192623311436185">Tijet et al. 2006</xref>), which can result in loss of control on PCNA, and as a result, its expression increased in the TCAB-induced hyperplastic lesions and culminated in SCC. It should be noted, however, that TCAB exposure may lead to increased expression of PCNA by other mechanisms than direct effect on the AhR, for example, by disrupting retinoid homeostasis and causing vitamin A deficiency, which can in turn lead to altered growth and differentiation of the oral gingival epithelium (<xref ref-type="bibr" rid="bibr80-0192623311436185">Yoshizawa et al. 2005</xref>). It has been demonstrated that higher expression of PCNA is a marker for the malignant potential of the oral mucosa and serves as an indicator for poor prognosis (<xref ref-type="bibr" rid="bibr61-0192623311436185">Tsuji et al. 1995</xref>; <xref ref-type="bibr" rid="bibr64-0192623311436185">Vered et al. 2007</xref>).</p>
<p>In the present study, cyclin-D1 showed a similar trend of expression compared to PCNA. This finding is somewhat analogous to the 4NQO model, in which its expression was found to increase with the severity of the dysplastic lesions (<xref ref-type="bibr" rid="bibr32-0192623311436185">Kanojia and Vaidya 2006</xref>). It has been shown that AhR can activate a series of genes whose protein products are critical in the G1-S transition of the cell cycle, namely, a series of cyclin-dependent kinases (CDK), among them CDK-6 (<xref ref-type="bibr" rid="bibr40-0192623311436185">Martinez et al. 2002</xref>). Cyclin-D1 works together with CDK6 and CDK4 and jointly increases cell proliferation (<xref ref-type="bibr" rid="bibr17-0192623311436185">Diamandis 2002</xref>). Furthermore, the gene encoding for cyclin-D1 has a binding region for the β-catenin after it leaves the membranous location, and in a complex with Tcf-4, it transports to the nucleus to become a transcription factor (<xref ref-type="bibr" rid="bibr17-0192623311436185">Diamandis 2002</xref>). In the present study, we found loss of membranous expression of β-catenin; however, we could not detect any nuclear expression. Presumably, activation of the cyclin-D1 is not performed by β-catenin in the TCAB model, but perhaps rather by the AhR route. In carcinomas of the head and neck, oral mucosa, larynx, and nasopharynx, higher expression of cyclin-D1 has been reported (<xref ref-type="bibr" rid="bibr13-0192623311436185">Das et al. 2011</xref>; <xref ref-type="bibr" rid="bibr15-0192623311436185">de Rosa et al. 1999</xref>; <xref ref-type="bibr" rid="bibr19-0192623311436185">Dong et al. 2001</xref>; <xref ref-type="bibr" rid="bibr22-0192623311436185">Gimenez-Conti et al. 1996</xref>; <xref ref-type="bibr" rid="bibr35-0192623311436185">Lamb and Ewen 2003</xref>; <xref ref-type="bibr" rid="bibr36-0192623311436185">Lin et al. 2006</xref>; <xref ref-type="bibr" rid="bibr57-0192623311436185">Staibano et al. 2001</xref>; <xref ref-type="bibr" rid="bibr73-0192623311436185">Xu et al. 1998</xref>). In addition, expression of membranous β-catenin was previously found to be reduced in oral SCC cases (<xref ref-type="bibr" rid="bibr2-0192623311436185">Bagutti et al. 1998</xref>; <xref ref-type="bibr" rid="bibr20-0192623311436185">El-Rouby 2011</xref>; <xref ref-type="bibr" rid="bibr37-0192623311436185">Lo Muzio et al. 1999</xref>; <xref ref-type="bibr" rid="bibr70-0192623311436185">Williams et al. 1998</xref>).</p>
<p>We have found that the expression of maspin was the highest in control animals, almost similarly high in GSH, less in CKH, and the lowest in SCC. Maspin is known to have a critical role in maintaining cellular homeostasis, in particular to guard cells from oxidative stress and keep them from going into a metabolism of glycolysis (<xref ref-type="bibr" rid="bibr9-0192623311436185">Cai et al. 2009</xref>; <xref ref-type="bibr" rid="bibr75-0192623311436185">Yin et al. 2005</xref>). Its expression in counteracting increased oxidative stress is demanded when cells are exposed to TCAB, since AhR is one of the main reasons for the activation of the gene encoding for the cytochrome P450 (CYP450) family that has a strong effect of increasing intracellular oxidative stress (<xref ref-type="bibr" rid="bibr40-0192623311436185">Martinez et al. 2002</xref>).</p>
<p>As the lesions of GSH, CKH, and SCC in the present study showed decreased expression of maspin, it can be assumed that the guardian effect of maspin is overruled, especially in CKH and mostly in SCC. From a study on one DLC on normal lung and lung cancer cell lines, it has been shown that AhR has the ability to suppress the transcriptional activity of the cell cycle protein p53 (<xref ref-type="bibr" rid="bibr40-0192623311436185">Martinez et al. 2002</xref>), which is known to be one of the major activators of the maspin gene (<xref ref-type="bibr" rid="bibr29-0192623311436185">Hendrix 2002</xref>). This can be an explanation of why the more extensive and penetrating lesions in the present study demonstrated less expression of maspin. In general, loss of maspin was correlated with poor prognosis in colon, uterus, breast, prostate, skin, thyroid, and oral SCC (<xref ref-type="bibr" rid="bibr1-0192623311436185">Amir et al. 2005</xref>; <xref ref-type="bibr" rid="bibr5-0192623311436185">Bettstetter et al. 2005</xref>; <xref ref-type="bibr" rid="bibr6-0192623311436185">Biliran and Sheng 2001</xref>; <xref ref-type="bibr" rid="bibr16-0192623311436185">Denk et al. 2007</xref>; <xref ref-type="bibr" rid="bibr52-0192623311436185">Shams et al. 2006</xref>; <xref ref-type="bibr" rid="bibr72-0192623311436185">Xu et al. 2005</xref>; <xref ref-type="bibr" rid="bibr76-0192623311436185">Yin et al. 2006</xref>; <xref ref-type="bibr" rid="bibr79-0192623311436185">Yoshizawa et al. 2009b</xref>; <xref ref-type="bibr" rid="bibr71-0192623311436185">Xia et al. 2000</xref>; <xref ref-type="bibr" rid="bibr74-0192623311436185">Yasumatsu et al. 2001</xref>).</p>
<p>α-Smooth muscle actin and SPARC were not a prominent feature of the stroma adjacent to TCAB-induced SCC. In contrast, α-SMA–positive stromal cells (myofibroblasts) are a remarkable finding of the stroma surrounding 4NQO-induced tongue SCC (<xref ref-type="bibr" rid="bibr21-0192623311436185">Fracalossi et al. 2011</xref>; <xref ref-type="bibr" rid="bibr64-0192623311436185">Vered et al. 2007</xref>) as well as in human patients, where their presence is associated with tumor stage, metastasis, and poor prognosis (<xref ref-type="bibr" rid="bibr34-0192623311436185">Kawashiri et al. 2009</xref>; <xref ref-type="bibr" rid="bibr65-0192623311436185">Vered et al. 2010</xref>), which further enhances the molecular differences between these animal models.</p>
<p>In summary, this is the first set of studies to report that rat gingivae exposed for a long time to doses of TCAB, a nongenotoxic compound, respond by developing epithelial hyperplastic lesions, which include benign GSH, benign but locally aggressive CKH, and malignant lesions in the form of low-grade, well-differentiated SCC. There appears to be a progression from the hyperplastic and cystic lesions toward malignancy based on the morphological changes that is supported by the relative expression of proteins associated with carcinogenesis. In order to prove that SCC develops from progression of CKH, or that CKH is a more advanced stage of GSH, studies showing the relationship among these lesions in a time-dependent manner have to follow.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p> We gratefully acknowledge the expert review of Dr. Mamta Behl and Dr. Janardhan Kyathanahalli from NIEHS, RTP, NC. Dr. Mamta Behl from NIEHS and Dr. Kyathanahalli Janardhan from ILS, RTP, NC.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn2-0192623311436185">
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-0192623311436185">
<p>The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This work was supported by the intramural program of the National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, NC. However, the statements, opinions, or conclusions contained herein do not necessarily represent the statements, opinions, or conclusions of NIEHS, NIH, or the United States government.</p>
</fn>
</fn-group>
<glossary content-type="abbr">
<title>Abbreviations</title>
<def-list>
<def-item>
<term id="term1-0192623311436185">4HAQO</term>
<def>
<p>4-hydroxyaminoquinoline-1-oxide</p>
</def>
</def-item>
<def-item>
<term id="term2-0192623311436185">4NQO</term>
<def>
<p>4-nitroquinoline 1-oxide</p>
</def>
</def-item>
<def-item>
<term id="term3-0192623311436185">AhR</term>
<def>
<p>aryl hydrocarbon receptor</p>
</def>
</def-item>
<def-item>
<term id="term4-0192623311436185">CDK</term>
<def>
<p>cyclin-dependent kinases</p>
</def>
</def-item>
<def-item>
<term id="term5-0192623311436185">CKH</term>
<def>
<p>cystic keratinizing hyperplasia</p>
</def>
</def-item>
<def-item>
<term id="term6-0192623311436185">DLC</term>
<def>
<p>dioxin-like compound</p>
</def>
</def-item>
<def-item>
<term id="term7-0192623311436185">GC</term>
<def>
<p>gas chromatography</p>
</def>
</def-item>
<def-item>
<term id="term8-0192623311436185">GSH</term>
<def>
<p>gingival squamous hyperplasia</p>
</def>
</def-item>
<def-item>
<term id="term9-0192623311436185">Maspin</term>
<def>
<p>mammary serine protease inhibitor</p>
</def>
</def-item>
<def-item>
<term id="term10-0192623311436185">NTP</term>
<def>
<p>National Toxicology Program</p>
</def>
</def-item>
<def-item>
<term id="term11-0192623311436185">PCB</term>
<def>
<p>polychlorinated biphenyl</p>
</def>
</def-item>
<def-item>
<term id="term12-0192623311436185">PCB118</term>
<def>
<p>2,3′,4,4′,5-pentachlorobiphenyl</p>
</def>
</def-item>
<def-item>
<term id="term13-0192623311436185">PCB126</term>
<def>
<p>3,3′,4,4′,5-pentachlorobiphenyl</p>
</def>
</def-item>
<def-item>
<term id="term14-0192623311436185">PCB153</term>
<def>
<p>2,2′,4,4′\,5,5'-hexachlorobiphenyl</p>
</def>
</def-item>
<def-item>
<term id="term15-0192623311436185">PCNA</term>
<def>
<p>proliferating cell nuclear antigen</p>
</def>
</def-item>
<def-item>
<term id="term16-0192623311436185">PeCDF</term>
<def>
<p>2,3,4,7,8-pentachloro-dibenzofuran</p>
</def>
</def-item>
<def-item>
<term id="term17-0192623311436185">SCC</term>
<def>
<p>squamous cell carcinoma</p>
</def>
</def-item>
<def-item>
<term id="term18-0192623311436185">SMA</term>
<def>
<p>smooth muscle actin</p>
</def>
</def-item>
<def-item>
<term id="term19-0192623311436185">TCAB</term>
<def>
<p>3,3′,4,4′-tetrachloroazobenzene</p>
</def>
</def-item>
<def-item>
<term id="term20-0192623311436185">TCDD</term>
<def>
<p>2,3,7,8-tetrachlorodibenzo-p-dioxin</p>
</def>
</def-item>
<def-item>
<term id="term21-0192623311436185">TEF</term>
<def>
<p>toxic equivalency factor.</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="bibr1-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amir</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Margaryan</surname>
<given-names>N. V.</given-names>
</name>
<name>
<surname>Odero-Marah</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Khalkhali-Ellis</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hendrix</surname>
<given-names>M. J.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cells</article-title>. <source>Cancer Biol Ther</source> <volume>4</volume>, <fpage>400</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr2-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bagutti</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Speight</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Watt</surname>
<given-names>F. M.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Comparison of integrin, cadherin, and catenin expression in squamous cell carcinomas of the oral cavity</article-title>. <source>J Pathol</source> <volume>186</volume>, <fpage>8</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr3-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bailer</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Portier</surname>
<given-names>C. J.</given-names>
</name>
</person-group> (<year>1988</year>). <article-title>Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples</article-title>. <source>Biometrics</source> <volume>44</volume>, <fpage>417</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr4-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bello</surname>
<given-names>I. O.</given-names>
</name>
<name>
<surname>Vered</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dayan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dobriyan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yahalom</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Alanen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nieminen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kantola</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Laara</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Salo</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Cancer-associated fibroblasts, a parameter of the tumor microenvironment, overcomes carcinoma-associated parameters in the prognosis of patients with mobile tongue cancer</article-title>. <source>Oral Oncol</source> <volume>47</volume>, <fpage>33</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr5-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bettstetter</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Woenckhaus</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wild</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Rummele</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Blaszyk</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hartmann</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hofstadter</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Dietmaier</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer</article-title>. <source>J Pathol</source> <volume>205</volume>, <fpage>606</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr6-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biliran</surname>
<given-names>H.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Sheng</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin</article-title>. <source>Cancer Res</source> <volume>61</volume>, <fpage>8676</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr7-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boorman</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Haseman</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Waters</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Hardisty</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Sills</surname>
<given-names>R. C.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Quality review procedures necessary for rodent pathology databases and toxicogenomic studies: the National Toxicology Program experience</article-title>. <source>Toxicol Pathol</source> <volume>30</volume>, <fpage>88</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr8-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brix</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Jokinen</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>N. J.</given-names>
</name>
<name>
<surname>Sells</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Nyska</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Characterization of bronchiolar metaplasia of the alveolar epithelium in female Sprague-Dawley rats exposed to 3,3′,4,4′,5-pentachlorobiphenyl (PCB126)</article-title>. <source>Toxicol Pathol</source> <volume>32</volume>, <fpage>333</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr9-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Q. Y.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Mammary serine protease inhibitor inhibits epithelial growth factor-induced epithelial-mesenchymal transition of esophageal carcinoma cells</article-title>. <source>Cancer</source> <volume>115</volume>, <fpage>36</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr10-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chlenski</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cohn</surname>
<given-names>S. L.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Modulation of matrix remodeling by SPARC in neoplastic progression</article-title>. <source>Semin Cell Dev Biol</source> <volume>21</volume>, <fpage>55</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr11-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Myers</surname>
<given-names>J. N.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy</article-title>. <source>J Dent Res</source> <volume>87</volume>, <fpage>14</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr12-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kashima</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kaku</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yokoyama</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Mutations in components of the Wnt signaling pathway in adenoid cystic carcinoma</article-title>. <source>Mod Pathol</source> <volume>17</volume>, <fpage>1475</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr13-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Das</surname>
<given-names>S. N.</given-names>
</name>
<name>
<surname>Khare</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>S. C.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Correlation of cyclin D1 expression with aggressive DNA pattern in patients with tobacco-related intraoral squamous cell carcinoma</article-title>. <source>Indian J Med Res</source> <volume>133</volume>, <fpage>381</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr14-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dayan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hirshberg</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Rotem</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bodner</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Experimental tongue cancer in desalivated rats</article-title>. <source>Oral Oncol</source> <volume>33</volume>, <fpage>105</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr15-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Rosa</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Staibano</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lo Muzio</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Delfino</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lucariello</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Coppola</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>De Rosa</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Scully</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Potentially malignant and malignant lesions of the lip. Role of silver staining nucleolar organizer regions, proliferating cell nuclear antigen, p53, and c-myc in differentiation and prognosis</article-title>. <source>J Oral Pathol Med</source> <volume>28</volume>, <fpage>252</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr16-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Denk</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Bettstetter</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wild</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Hoek</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bataille</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Dietmaier</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Bosserhoff</surname>
<given-names>A. K.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Loss of maspin expression contributes to a more invasive potential in malignant melanoma</article-title>. <source>Pigment Cell Res</source> <volume>20</volume>, <fpage>112</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr17-0192623311436185">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Diamandis</surname>
<given-names>E. P.</given-names>
</name>
<name>
<surname>Fritsche</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lilja</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>D. W.</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>M.</given-names>
</name>
</person-group>, eds. (<year>2002</year>) <source>Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications</source>. <publisher-name>AACC Press</publisher-name>, <publisher-loc>Philadelphia, PA</publisher-loc>.</citation>
</ref>
<ref id="bibr18-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diehl</surname>
<given-names>J. A.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Cycling to cancer with cyclin D1</article-title>. <source>Cancer Biol Ther</source> <volume>1</volume>, <fpage>226</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr19-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sui</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sugimoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tokuda</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Cyclin D1-CDK4 complex, a possible critical factor for cell proliferation and prognosis in laryngeal squamous cell carcinomas</article-title>. <source>Int J Cancer</source> <volume>95</volume>, <fpage>209</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr20-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Rouby</surname>
<given-names>D. H.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Histological and immunohistochemical evaluation of the chemopreventive role of lycopene in tongue carcinogenesis induced by 4-nitroquinoline-1-oxide</article-title>. <source>Arch Oral Biol</source> <volume>56</volume>, <fpage>664</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr82-0192623311436185">
<citation citation-type="journal">
<collab collab-type="author">Food and Drug Administration</collab>. (<year>1987</year>). <article-title>Good laboratory regulations. Final rule 21 CFR 58 Fed Reg</article-title>. <volume>52</volume>, <fpage>33768</fpage>–<lpage>33782</lpage>.</citation>
</ref>
<ref id="bibr21-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fracalossi</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Comparini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Funabashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Godoy</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Iwamura</surname>
<given-names>E. S.</given-names>
</name>
<name>
<surname>Nascimento</surname>
<given-names>F. D.</given-names>
</name>
<name>
<surname>Nader</surname>
<given-names>H. B.</given-names>
</name>
<name>
<surname>Oshima</surname>
<given-names>C. T.</given-names>
</name>
<name>
<surname>Ribeiro</surname>
<given-names>D. A.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Ras gene mutation is not related to tumour invasion during rat tongue carcinogenesis induced by 4-nitroquinoline 1-oxide</article-title>. <source>J Oral Pathol Med</source> <volume>40</volume>, <fpage>325</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr22-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gimenez-Conti</surname>
<given-names>I. B.</given-names>
</name>
<name>
<surname>Collet</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Lanfranchi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Itoiz</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Luna</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S. X.</given-names>
</name>
<name>
<surname>Benedict</surname>
<given-names>W. F.</given-names>
</name>
<name>
<surname>Conti</surname>
<given-names>C. J</given-names>
</name>
</person-group>. (<year>1996</year>). <article-title>p53, Rb, and cyclin D1 expression in human oral verrucous carcinomas</article-title>. <source>Cancer</source> <volume>78</volume>, <fpage>17</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr23-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer</article-title>. <source>Adv Cancer Res</source> <volume>68</volume>, <fpage>67</fpage>–<lpage>108</lpage>.</citation>
</ref>
<ref id="bibr24-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harper</surname>
<given-names>P. A.</given-names>
</name>
<name>
<surname>Riddick</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Okey</surname>
<given-names>A. B.</given-names>
</name>
</person-group> (<year>2006</year>) <article-title>Regulating the regulator: Factors that control levels and activity of the aryl hydrocarbon receptor</article-title>. <source>Biochem Pharmacol</source> <volume>72</volume>, <fpage>267</fpage>–<lpage>279</lpage>.</citation>
</ref>
<ref id="bibr25-0192623311436185">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Hartl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2009</year>). <source>Genetics: Analysis of Genes and Genomes</source>. <publisher-name>Jones and Bartlett Learning</publisher-name>, <publisher-loc>Boston, MA</publisher-loc>.</citation>
</ref>
<ref id="bibr26-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashiguchi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Akamine</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Miyatake</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hara</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Toriya</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Aono</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fukuyama</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Okumura</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>1987</year>). <article-title>Histological study on the gingiva of the patient with yusho and of PCB-poisoned monkeys [in Japanese]</article-title>. <source>Fukuoka Igaku Zasshi</source> <volume>78</volume>, <fpage>259</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr27-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashiguchi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Akamine</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nakano</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Aono</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fukuyama</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>1983</year>). <article-title>Ultrastructure of the gingival epithelium of the monkeys with experimental PCB intoxication[in Japanese]</article-title>. <source>Fukuoka Igaku Zasshi</source> <volume>74</volume>, <fpage>246</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr28-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashiguchi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Toriya</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Anan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Akamine</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aono</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fukuyama</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Okumura</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>1995</year>). <article-title>An epidemiologic examination on the prevalence of the periodontal diseases and oral pigmentation in Yusho patients [in Japanese]</article-title>. <source>Fukuoka Igaku Zasshi</source>, <volume>86</volume>, <fpage>256</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr29-0192623311436185">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Hendrix</surname>
<given-names>M</given-names>
</name>
</person-group>. (<year>2002</year>). <source>Maspin</source>, <publisher-name>Landes Bioscience Medical Handbook Publisher</publisher-name>: <publisher-loc>Georgetown, Texas</publisher-loc>.</citation>
</ref>
<ref id="bibr30-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hill</surname>
<given-names>R. H.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Rollen</surname>
<given-names>Z. J.</given-names>
</name>
<name>
<surname>Kimbrough</surname>
<given-names>R. D.</given-names>
</name>
<name>
<surname>Groce</surname>
<given-names>D. F.</given-names>
</name>
<name>
<surname>Needham</surname>
<given-names>L. L.</given-names>
</name>
</person-group> (<year>1981</year>). <article-title>Tetrachloroazobenzene in 3,4-dichloroaniline and its herbicidal derivatives: propanil, diuron, linuron, and neburon</article-title>. <source>Arch Environ Health</source> <volume>36</volume>, <fpage>11</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr31-0192623311436185">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Hollander</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wolfe</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>1973</year>). <source>Nonparametric Statistical Methods</source>, <publisher-name>Wiley</publisher-name>, <publisher-loc>New York, NY</publisher-loc>.</citation>
</ref>
<ref id="bibr32-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanojia</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Vaidya</surname>
<given-names>M. M</given-names>
</name>
</person-group>. (<year>2006</year>). <article-title>4-nitroquinoline-1-oxide induced experimental oral carcinogenesis</article-title>. <source>Oral Oncol</source> <volume>42</volume>, <fpage>655</fpage>–<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr33-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kato</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kawashiri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yoshizawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kitahara</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Okamune</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sugiura</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Noguchi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>E</given-names>
</name>
</person-group>. (<year>2011</year>). <article-title>Expression form of p53 and PCNA at the invasive front in oral squamous cell carcinoma: correlation with clinicopathological features and prognosis</article-title>. <source>J Oral Pathol Med</source> <comment>doi: 10.1111/j.1600-0714.2011.01032.x. [Epub ahead of print]</comment>.</citation>
</ref>
<ref id="bibr34-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawashiri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Noguchi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hase</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nakaya</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ohara</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Significance of stromal desmoplasia and myofibroblast appearance at the invasive front in squamous cell carcinoma of the oral cavity</article-title>. <source>Head Neck</source> <volume>31</volume>, <fpage>1346</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr35-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamb</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ewen</surname>
<given-names>M. E.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Cyclin D1 and molecular chaperones: implications for tumorigenesis</article-title>. <source>Cell Cycle</source> <volume>2</volume>, <fpage>525</fpage>–<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr36-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>H. S.</given-names>
</name>
<name>
<surname>Berry</surname>
<given-names>G. J.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Fee</surname>
<given-names>W. E., </given-names>
<suffix>Jr.</suffix>
</name>
</person-group> (<year>2006</year>). <article-title>Cyclin D1 and p16 expression in recurrent nasopharyngeal carcinoma</article-title>. <source>World J Surg Oncol</source> <volume>4</volume>, <fpage>62</fpage>.</citation>
</ref>
<ref id="bibr37-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lo Muzio</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Staibano</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pannone</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Grieco</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mignogna</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Cerrato</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Testa</surname>
<given-names>N. F.</given-names>
</name>
<name>
<surname>De Rosa</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Beta- and gamma-catenin expression in oral squamous cell carcinomas</article-title>. <source>Anticancer Res</source> <volume>19</volume>, <fpage>3817</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr38-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loe</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Karring</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hara</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>1972</year>). <article-title>The site of mitotic activity in rat and human oral epithelium</article-title>. <source>Scand J Dent Res</source> <volume>80</volume>, <fpage>111</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr39-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maga</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hubscher</surname>
<given-names>U.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Proliferating cell nuclear antigen (PCNA): a dancer with many partners</article-title>. <source>J Cell Sci</source> <volume>116</volume>, <fpage>3051</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr40-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Afshari</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Bushel</surname>
<given-names>P. R.</given-names>
</name>
<name>
<surname>Masuda</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>N. J.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Differential toxicogenomic responses to 2,3,7,8-tetrachlorodibenzo-p-dioxin in malignant and nonmalignant human airway epithelial cells</article-title>. <source>Toxicol Sci</source> <volume>69</volume>, <fpage>409</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr41-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McNulty</surname>
<given-names>W. P.</given-names>
</name>
</person-group> (<year>1985</year>). <article-title>Toxicity and fetotoxicity of TCDD, TCDF and PCB isomers in rhesus macaques (Macaca mulatta)</article-title>. <source>Environ Health Perspect</source> <volume>60</volume>, <fpage>77</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr42-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murray</surname>
<given-names>I. A.</given-names>
</name>
<name>
<surname>Morales</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Flaveny</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>DiNatale</surname>
<given-names>B. C.</given-names>
</name>
<name>
<surname>Chiaro</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gowdahalli</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Amin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Perdew</surname>
<given-names>G. H.</given-names>
</name>
</person-group> (<year>2010</year>) <article-title>Evidence for ligand-mediated selective modulation of aryl hydrocarbon receptor activity</article-title>. <source>Mol Pharmacol</source> <volume>77</volume>, <fpage>247</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr43-0192623311436185">
<citation citation-type="book">
<collab collab-type="author">National Toxicology Program (NTP)</collab> (<year>2009</year>). <source>Toxicology and Carcinogenesis Studies of 3,30,4,40-Tetrachloroazobenzene (CAS No. 14047-09-7) in Sprague Dawley rats and B6C3F1 mice (Gavage studies)</source>. <comment>Toxicity Report Series No. 558. NIH Publication No. 09-5899</comment>. <publisher-name>U. S. Department of Health and Human Services, Public Health Service, National Institutes of Health</publisher-name>, <publisher-loc>Research Triangle Park, NC</publisher-loc>.</citation>
</ref>
<ref id="bibr83-0192623311436185">
<citation citation-type="book">
<collab collab-type="author">National Research Council</collab> (<year>1996</year>).<article-title>Guide for the Care and Use of Laboratory Animals</article-title>. <publisher-name>National Academy Press</publisher-name>: <publisher-loc>Washington, DC</publisher-loc>.</citation>
</ref>
<ref id="bibr84-0192623311436185">
<citation citation-type="web">
<collab collab-type="author">National Toxicology Program Websit</collab>, <ext-link ext-link-type="uri" xlink:href="http://ntp.niehs.nih.gov/ntpweb/index.cfm?objectid1/492E705C7-F1F6-975E-72D23026B1645EB9">http://ntp.niehs.nih.gov/ntpweb/index.cfm?objectid1/492E705C7-F1F6-975E-72D23026B1645EB9</ext-link>.</citation>
</ref>
<ref id="bibr44-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nyska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jokinen</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Brix</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Sells</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Wyde</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Orzech</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Haseman</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Flake</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>N. J.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Exocrine pancreatic pathology in female Harlan Sprague-Dawley rats after chronic treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin and dioxin-like compounds</article-title>. <source>Environ Health Perspect</source> <volume>112</volume>, <fpage>903</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr45-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oyama</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ochiai</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Akimoto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Oda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yanagihara</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nagafuchi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tsukita</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shibamoto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group>. (<year>1994</year>). <article-title>A truncated beta-catenin disrupts the interaction between E-cadherin and alpha-catenin: a cause of loss of intercellular adhesiveness in human cancer cell lines</article-title>. <source>Cancer Res</source> <volume>54</volume>, <fpage>6282</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr46-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pillai</surname>
<given-names>U. A.</given-names>
</name>
<name>
<surname>Ziegler</surname>
<given-names>T. L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D. X.</given-names>
</name>
<name>
<surname>Kattnig</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>McClure</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liebler</surname>
<given-names>D. C.</given-names>
</name>
<name>
<surname>Mayersohn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sipes</surname>
<given-names>I. G</given-names>
</name>
</person-group>. (<year>1996</year>) <article-title>3,3′,4,4′-tetrachloroazobenzene absorption, disposition, and metabolism in male Fischer 344 rats</article-title>. <source>Drug Metab Dispos</source> <volume>24</volume>, <fpage>238</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr47-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Podhajcer</surname>
<given-names>O. L.</given-names>
</name>
<name>
<surname>Benedetti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Girotti</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Prada</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Salvatierra</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Llera</surname>
<given-names>A. S.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host</article-title>. <source>Cancer Metastasis Rev</source> <volume>27</volume>, <fpage>523</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr48-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poland</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Clover</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kende</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>DeCamp</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Giandomenico</surname>
<given-names>C. M</given-names>
</name>
</person-group>. (<year>1976</year>). <article-title>3,4,3',4'-Tetrachloro azoxybenzene and azobenzene: potent inducers of aryl hydrocarbon hydroxylase</article-title>. <source>Science</source> <volume>194</volume>, <fpage>627</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr49-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pollack</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Barth</surname>
<given-names>A. I.</given-names>
</name>
<name>
<surname>Altschuler</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>Mostov</surname>
<given-names>K. E.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Dynamics of beta-catenin interactions with APC protein regulate epithelial tubulogenesis</article-title>. <source>J Cell Biol</source> <volume>137</volume>, <fpage>1651</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr50-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Portier</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Bailer</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>1989</year>). <article-title>Testing for increased carcinogenicity using a survival-adjusted quantal response test</article-title>. <source>Fundam Appl Toxicol</source> <volume>12</volume>, <fpage>731</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr51-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramot</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nyska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lieuallen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Maly</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Flake</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kissling</surname>
<given-names>G. E.</given-names>
</name>
<name>
<surname>Brix</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Malarkey</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Hooth</surname>
<given-names>M. J.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Inflammatory and chloracne-like skin lesions in B6C3F1 mice exposed to 3,3′,4,4′-tetrachloroazobenzene for 2 years</article-title>. <source>Toxicology</source> <volume>265</volume>, <fpage>1</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr52-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shams</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Samaka</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Shams</surname>
<given-names>M. E.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Maspin protein expression: a special feature of papillary thyroid carcinoma</article-title>. <source>J Egypt Natl Canc Inst</source> <volume>18</volume>, <fpage>274</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr53-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimono</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ishikawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Enokiya</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Muramatsu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Matsuzaka</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Abiko</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yamaza</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kido</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Biological characteristics of the junctional epithelium</article-title>. <source>J Electron Microsc (Tokyo)</source> <volume>52</volume>, <fpage>627</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr54-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shiozaki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Oka</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tamura</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Monden</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>E-cadherin mediated adhesion system in cancer cells</article-title>. <source>Cancer</source> <volume>77</volume>, <fpage>1605</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr55-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shojaei</surname>
<given-names>A. H.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Buccal mucosa as a route for systemic drug delivery: a review</article-title>. <source>J Pharm Pharm Sci</source> <volume>1</volume>, <fpage>15</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr56-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>B. P.</given-names>
</name>
<name>
<surname>Nyska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kissling</surname>
<given-names>G. E.</given-names>
</name>
<name>
<surname>Lieuallen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Johansson</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Malarkey</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Hooth</surname>
<given-names>M. J.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Urethral carcinoma and hyperplasia in male and female B6C3F1 mice treated with 3,3′,4,4′-tetrachloroazobenzene (TCAB)</article-title>. <source>Toxicol Pathol</source> <volume>38</volume>, <fpage>372</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr57-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Staibano</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lo Muzio</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pannone</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mezza</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Argenziano</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Vetrani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lucariello</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Franco</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Errico</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>De Rosa</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>DNA ploidy and cyclin D1 expression in basal cell carcinoma of the head and neck</article-title>. <source>Am J Clin Pathol</source> <volume>115</volume>, <fpage>805</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr58-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tani</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Maronpot</surname>
<given-names>R. R.</given-names>
</name>
<name>
<surname>Foley</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Haseman</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>N. J.</given-names>
</name>
<name>
<surname>Nyska</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Follicular epithelial cell hypertrophy induced by chronic oral administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin in female Harlan Sprague-Dawley rats</article-title>. <source>Toxicol Pathol</source> <volume>32</volume>, <fpage>41</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr59-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tijet</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Boutros</surname>
<given-names>P. C.</given-names>
</name>
<name>
<surname>Moffat</surname>
<given-names>I. D.</given-names>
</name>
<name>
<surname>Okey</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Tuomisto</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pohjanvirta</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Aryl hydrocarbon receptor regulates distinct dioxin-dependent and dioxin-independent gene batteries</article-title>. <source>Mol Pharmacol</source> <volume>69</volume>, <fpage>140</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr60-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tryphonas</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Zawidzka</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Mes</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Charbonneau</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>1986</year>). <article-title>A pilot study in adult rhesus monkeys (M. mulatta) treated with Aroclor 1254 for two years</article-title>. <source>Toxicol Pathol</source> <volume>14</volume>, <fpage>1</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr61-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsuji</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mimura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Kanekawa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shinozaki</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>1995</year>). <article-title>The significance of PCNA and p53 protein in some oral tumors</article-title>. <source>Int J Oral Maxillofac Surg</source> <volume>24</volume>, <fpage>221</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr62-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Birgelen</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Hebert</surname>
<given-names>C. D.</given-names>
</name>
<name>
<surname>Wenk</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Grimes</surname>
<given-names>L. K.</given-names>
</name>
<name>
<surname>Chapin</surname>
<given-names>R. E.</given-names>
</name>
<name>
<surname>Mahler</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Travlos</surname>
<given-names>G. S.</given-names>
</name>
<name>
<surname>Bucher</surname>
<given-names>J. R.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Toxicity of 3,3′,4,4′-tetrachloroazobenzene in rats and mice</article-title>. <source>Toxicol Appl Pharmacol</source> <volume>156</volume>, <fpage>147</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr64-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vered</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Allon</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Buchner</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dayan</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Stromal myofibroblasts and malignant transformation in a 4NQO rat tongue carcinogenesis model</article-title>. <source>Oral Oncol</source> <volume>43</volume>, <fpage>999</fpage>–<lpage>1006</lpage>.</citation>
</ref>
<ref id="bibr65-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vered</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dayan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yahalom</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Dobriyan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Barshack</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bello</surname>
<given-names>I. O.</given-names>
</name>
<name>
<surname>Kantola</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Salo</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Cancer-associated fibroblasts and epithelial-mesenchymal transition in metastatic oral tongue squamous cell carcinoma</article-title>. <source>Int J Cancer</source> <volume>127</volume>, <fpage>1356</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr66-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vered</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yarom</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Dayan</surname>
<given-names>D</given-names>
</name>
</person-group>. (<year>2005</year>). <article-title>4NQO oral carcinogenesis: animal models, molecular markers and future expectations</article-title>. <source>Oral Oncol</source> <volume>41</volume>, <fpage>337</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr67-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vondracek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xi</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Larsson</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Mace</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pfeifer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tjalve</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Donato</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Gomez-Lechon</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Grafstrom</surname>
<given-names>R. C.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Cytochrome P450 expression and related metabolism in human buccal mucosa</article-title>. <source>Carcinogenesis</source> <volume>22</volume>, <fpage>481</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr68-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walker</surname>
<given-names>N. J.</given-names>
</name>
<name>
<surname>Wyde</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Nyska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bucher</surname>
<given-names>J. R.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Comparison of chronic toxicity and carcinogenicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in 2-year bioassays in female Sprague-Dawley rats</article-title>. <source>Mol Nutr Food Res</source> <volume>50</volume>, <fpage>934</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr69-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watanabe</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Petro</surname>
<given-names>B. J.</given-names>
</name>
<name>
<surname>Sevandal</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Anshuman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jovanovic</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tyner</surname>
<given-names>A. L.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Histochemical examination of periodontal junctional epithelium in p21/p27 double knockout mice</article-title>. <source>Eur J Oral Sci</source> <volume>112</volume>, <fpage>253</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr70-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>H. K.</given-names>
</name>
<name>
<surname>Sanders</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Jankowski</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Landini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>A. M.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Expression of cadherins and catenins in oral epithelial dysplasia and squamous cell carcinoma</article-title>. <source>J Oral Pathol Med</source> <volume>27</volume>, <fpage>308</fpage>–<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr71-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>Y. K.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>El-Naggar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>M. C.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma</article-title>. <source>Oncogene</source> <volume>19</volume>, <fpage>2398</fpage>–<lpage>403</lpage>.</citation>
</ref>
<ref id="bibr72-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Quddus</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Steinhoff</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lawrence</surname>
<given-names>W. D.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Maspin expression in CIN 3, microinvasive squamous cell carcinoma, and invasive squamous cell carcinoma of the uterine cervix</article-title>. <source>Mod Pathol</source> <volume>18</volume>, <fpage>1102</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr73-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gimenez-Conti</surname>
<given-names>I. B.</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Collet</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Luna</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Lanfranchi</surname>
<given-names>H. E.</given-names>
</name>
<name>
<surname>Spitz</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Conti</surname>
<given-names>C. J.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Alterations of p53, cyclin D1, Rb, and H-ras in human oral carcinomas related to tobacco use</article-title>. <source>Cancer</source> <volume>83</volume>, <fpage>204</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr74-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yasumatsu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nakashima</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hirakawa</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kumamoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kuratomi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tomita</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Komiyama</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Maspin expression in stage I and II oral tongue squamous cell carcinoma</article-title>. <source>Head Neck</source> <volume>23</volume>, <fpage>962</fpage>–<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr75-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Finley</surname>
<given-names>R. L.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Sakr</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Tumor-suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase</article-title>. <source>J Biol Chem</source> <volume>280</volume>, <fpage>34985</fpage>–<lpage>96</lpage>.</citation>
</ref>
<ref id="bibr76-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lockett</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Biliran</surname>
<given-names>H.</given-names>
<suffix>Jr.,</suffix>
</name>
<name>
<surname>Blouse</surname>
<given-names>G. E.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Anagli</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cher</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system</article-title>. <source>Cancer Res</source> <volume>66</volume>, <fpage>4173</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr77-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshihara</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ozawa</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yoshimura</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Masuda</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yamaryo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kuroki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Murai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Akagi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yamanaka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Omae</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Okumura</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ohnishi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Iwashita</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kohno</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ohnishi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ishibashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kikuchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fukuyama</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Anan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Akamine</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aono</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>1979</year>). <article-title>Preliminary studies on the experimental PCB poisoning in rhesus monkeys [in Japanese]</article-title>. <source>Fukuoka Igaku Zasshi</source> <volume>70</volume>, <fpage>135</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr78-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshizawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Brix</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Sells</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Jokinen</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Wyde</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Orzech</surname>
<given-names>D. P.</given-names>
</name>
<name>
<surname>Kissling</surname>
<given-names>G. E.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>N. J.</given-names>
</name>
<name>
<surname>Nyska</surname>
<given-names>A</given-names>
</name>
</person-group>. (<year>2009a</year>). <article-title>Reproductive lesions in female Harlan Sprague-Dawley rats following two-year oral treatment with dioxin and dioxin-like compounds</article-title>. <source>Tocixol Pathol</source> <volume>37</volume>, <fpage>921</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr79-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshizawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nozaki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Okamune</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kitahara</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ohara</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kawashiri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2009b</year>). <article-title>Loss of maspin is a negative prognostic factor for invasion and metastasis in oral squamous cell carcinoma</article-title>. <source>J Oral Pathol Med</source> <volume>38</volume>, <fpage>535</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr80-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshizawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>N. J.</given-names>
</name>
<name>
<surname>Jokinen</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Brix</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Sells</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Marsh</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wyde</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Orzech</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Haseman</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Nyska</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Gingival carcinogenicity in female Harlan Sprague-Dawley rats following two-year oral treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin and dioxin-like compounds</article-title>. <source>Toxicol Sci</source> <volume>83</volume>, <fpage>64</fpage>–<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr81-0192623311436185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhurinsky</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shtutman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ben-Ze'ev</surname>
<given-names>A</given-names>
</name>
</person-group>. (<year>2000</year>). <article-title>Plakoglobin and beta-catenin: protein interactions, regulation and biological roles</article-title>. <source>J Cell Sci</source> <volume>113</volume> (<issue>Pt 18</issue>), <fpage>3127</fpage>–<lpage>39</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>